MIHS IGA ATTACHMENT 2.PDF

SECTION V ATTACHMENT 2 RYAN WHITE PART A PROGRAM
This Attachment consists of the Maricopa Integrated Health Systems response to the Maricopa County
Ryan White Part A Program, Request for Proposal will consist of the response to 13126-RFP for
Outpatient Ambulatory Medical Care Services. This portion of the Intergovernmental Agreement shall
be a Fee for Service arrangement utilizing the Arizona Health Care Cost Containment System, Fee for
Service rate, in place during the time the service(s) is/are performed.
Index of Attachments
Attachment 2 consists of the following original documents:
Attachment 2- A: Service Provider Application
Attachment 2-B: Budget for Outpatient Ambulatory Medical Care
Attachment 2-C: Narrative Scope of Work
Attachment 2-D: M1HS Staff Licenses and Resumes
Attachment 2-E: M1HS References
Attachment 2-F: MINS Indirect Cost Agreement
Attachment 2-6: MIRS Org Chart

Attachment 2-A
SERVICE PROVIDER APPLICATION
Organization: Maricopa Integrated Health System
Address: 2601 E. Roosevelt St.
City: Phoenix State: AZ Zip: 85008
Telephone: 602-344-2629
Executive Director/CEO: Stephen A. Purves, Preside
Person completing this form: Cheri Tomlinson Contact Telephone:
602-344-2629
Legal Status: El Nonprofit 50I-C3 Ei Corporation LLC riPartnershOther
Maricopa County Sp%
Years in Business: 134 years as an organizatii
Maricopa County Vendor Registration Complete: ZYes Do Vendor Number: W000007745-9
Site and Locations where services will be provided under this contract:
Service Site Location #1:
Organization: McDowell Healthcare Center
Address: 1101 N. Central Ave,
City : Phoenix State: Az Zip: 85004
Telephone: 602-344-6550
Service Site Location #2:
Organization:
Address:
City: State: Zip:
Telephone:
Note: If you propose more than two (2) Service Site Locations please include an additional attachment B
identifying those locations.
What Geographic Location(s) do you plan to serve (See Exhibit3)? M IHS will provide services through%
Upon Award of a Contract, for this service, it is required that the Contractor shall comply with all Terms and
Conditions o Uthis Soli ion. Can your Organization meet and comply with all of the Terms and Conditions at this
time? Yes or No
Can your Organization meet all of the Terms and Conditions at the time of the contract award? []Yes or
No
1

ATTACHMENT B
SERVICE PROVIDER APPLICATION
If your response is no to this question, please identify the Term and Condition and describe how your Organization
will meet the requirement:
Do you currently provide services for HIV/AIDS Clients? ig Yes or Ell No
If yes, do you receive other grant funds for these programs? i Yes or ENO
Please list who provides these funds and how long you have been funded below.
Grant fund 1: Please see attached addeii Since:
Grant fund 2: Since:
Grant fund 3: Since:
Do you have a financial system in place that will allow you to separate income and expenditures related to each
grant and general funds? 111 INo
Yes I
If yes, describe your system:
MINS creates grant cost centers to track income and expenses separately.
If no, describe how you would be able to implement a system:
Do you have a financial system in place that will allow you to perform third party billing to ensure that funds used
under this contract are the payer of last resort (applicable if other payer sources are possible)? Yes EN°
0
If no, describe how you would be able to implement a system for this:
Organizational Chart attached? i Yes or ONG
Resumes attached? es or ON°
Licenses /Credentials attached? 1 Yes or No
,
2

Maricopa Integrated Health System
RWPA Outpatient Ambulatory Medical Care Service
Solicitation 13126-RFP
Attachment B Service Provider Application
List of HIV/AIDS Grant Funds Addendum
Please list who provides these funds and how long you have been funded:
Service Catefory Funder Start Date Stop Date
Outpatient/Ambulatory Medical Ryan White White Part A 03/01/199_4_ Current
Care R an While Part C - 01/01/1 -991 —Current
----- - . Ryan White Part D 08/01/1998 Current
Medical Case Management Ryan White Part A "6-1/a/-2-.011 08/61/2011
Ryan White Part D 08/01/1998 Current
Ryan White Part A 04i01/2007 Current
Oral Health Care Ryan White Part C 01/01/1991 Current
Ryan White Part b _ 08/01/1998 Current
Early Intervention Services (RWPA) Ryan White Part A 09/12/2011 Current
Early Intervention Services (MAI) Ryan White Part A 11/22/2011 Current
Early Intervention Services Part C) Ryan White Part C 01/01/1991 Current
Mental Health Services Ryan White Part A 03/01/1994 Current
R n White Part C__ 01/0111991 Current -
Substance Abuse Services, , Ryan White Part A 03/01/199.4 — Current
Oup ent _Ryan White Part C 01/01/1991 Current
Case Management, Non-medical Ryan White Part C 01/01/1991 06/30/2013 I
Ryan White Part B 04/01/2005 03/31/2008
Treatment Adherence Services MAC Cosmetics AIDS Fund 10118/2008 09/30/2009
Bnehringer-ingelheim
, Pharmaceuticals 04/07/2008 03/31/2009
HIV Prevention Centers for Disease Control 10/01/2010 Current
& Prevention
Child Watch Services Ryan White Part D _ 08101/1998 Current
Outreach Services Ryan White Part D 08/01/1998 07/31/2012
Unrestricted Funding Aunt Rita's Foundation 12/01/2005 Current
._ Soroptonnst International 09/01/2005 08/31/2016

Attachment 2-B
Maricopa County
Ryan White Part A - Budget Documentation
DATE PREPARED 10/22/13
PREPARED BY Phyllis Hardy
NAME OF ORGANIZATION: Maricopa Integrated Health System
Fed. Employee ID # (FEIN) 86-0530701
DUNS # 186507216
ADDRESS: 2601 E Roosevelt Road
Phoenix, AZ 85008
AUTHORIZED CONTACT Dr Robert Fromm, Chief Medical Officer
TELEPHONE (602) 344-5503 FAX (602_044-5190
E-MAiL robert.fromm@mihs.org
PRIMARY CONTACT
C rl eri TO Fri 0 71
TELEPHONE 602-344-2629 FAX 602-344-2633
EMAIL cheri.tomlinson@mihs.orig
CONTRACT NUMBER c-31-10-001-3-00
SERVICE CATEGORY Outpatient Primary Medical Care
BUDGET PERIOD: 3/1/2014 2/28/2015
Start Date End Date
CONTRACT AMOUNT $2,548,949.96
By submission of this budget, the Provider certifies that they have read the List of Unallowable Costs under
the Ryan White Part A Program and agree to follow the NRSA specific standards related to Unallowable Costs,
In addition, the following documents must be submitted with your budget proposal (Check the appropriate boxes)
If applicable, Negotiated Indirect Cost Agreement is attached DI Cost Allocation Policy is attached (required)
Cover Page
Budget Template
Effective 311/2013
Revised 311/2013
Reviewed 3/112013

Marlcopa County
Ryan White Part A Grant
Contractor Budged Summary
Dale Prepared: 10/2212013
(Section I)
Organization Maricopa integrated Health System
Service Category Outpatient Primary Medical Care
Budget Period 1M2014 Through 212B/2015
(Section II) Contract Amount I $2,5413,949.961
Operating Expenses Addi:niseal,e Dukdazi Dirutt SemIve &Wye. cAal
0.00
Personnel: Salaries
Personnel: FringelBeneflts
Subtotal: Personnel/Fringe Benefits
Other 0 rating Ex nses
Travel .
- -
Suppliers _ - -
Equipment . - -
Contractual . - -
_
Program Su_pport - 2,317,227.24 2,317 227.24
Other Professional Services - -
Subtotal: Other Operating Expenses 2,317,227.24 2,317,227.24
Total Operating Expenses —E 2,317,227.24 2,317,227.24
(Personnel and Other Direct Costs)
Indirect Costs 231,722.72 .1111..1111. 231,722.72
Enter indirect Cost Rate 10.00% Providers claiming an indirect cost must submit their most current negotiated indirect costs
may net exceed 10% at Direct Coal.) rate agreement issued by the cognizant federal agency with their budget.
(Total Costs of Contract 231,722.72 2,317,227.24 I 2,548,949.96]
(Arimln-Perceni of Direct Costs) 10.00%
:drroistrauon 75), not exceed 111% olDiectCst9
CONTRACT BALANCE (Contract Revenue less Total Costs of Contract) $ j0.00)
I:[(4,70 adienx sttc.,ad /*re
Budget Summary
Budget Terdetele
Effective W172013
Revised 3h12013
Reviewed 31112013

—
10122120131 . - .. -
... ---
.
-
5 S
I I —.. .1.5
- - . • -
Prepared:
laMMIE
Date _
s .
, , r '
• ' -Js
. -
i.....
..1_ 1 .! -I
- - - - - '
004 .
MMIlinli
0
A r
Rate
Cate
Benefit
Maths''
Fnnge
rn3iy
___I
Pi
___L__----1.-
chart. Outpalir-rti
I I
- ' - - -
following Calculation Tim ,.
0%
the !Auto Health . .
in :11 • 5 i 5 1$ S
;
listed - - - - - -
Entry Integrated
be Mrnit
%Iw
to Provider
are kora Prcent
grant Mui 5 , is IS is IS 5
I _
A StifYinci
Part 1 j :. Fit FTE
1
White 01050 OC&D 00000 iEumo.i 0.00
mow 0.CCIOD 0.0000
0
Ryan L I 1 1
__L_____±..__Ls
ISMIIMIEMiIIIIIIMI11110.1111I1111MIONI1111.1.111IMIII
this
from I 1
.1L
part
L
or
.
full
in
paid
staff
_
All Tota;
L I
,r________J
Staffing Deuription Deeenptlen Clisalplion 41Dincnrdien efeiTAriiiior 13escetilicel Tempiate 311/2013 31112013 31112013
Personnel
1 3 1 I 6 7 8
Personnel Budget Effective Revised Reviewed

10122/2013
Prepared:
Date
Cer!
Medical
Primary
OutpEllen1
r
System
Rasa
Calculation Integrated
Auto
I Mansops
Entry 2)
Provider 2 at
(Pine
Sheet
Coomustion aixo
I a
2)
2 of
Page
(
Sheet -
Continuation -7
Conanuation Template 3/1/2013 311/2013 31112013
Staffing
2 1 1 1 1 Personnel Budget Effeclive Revised Reviewed

TRAVEL I ',wrier Ent,/ I At, Cee,•te• I
Rile Reword
Tiaval tan be budgeled or the COW .1 'lap mileage ar01 other travel aasuageted with Ryan 'Mate Rad A
1 Miens Wage lint be budgeted lilting gm sanded reaullion ea of movably mite ha • ha trna staff person .12 months A We lee per mail
tried by your organization • Me amber of FTE(s) burigelari who WIl travel to provide services nada, lho grant
E nter only Inc F T•s• trave awl provale a Narrative Just cation including who Will navel ard why
.1[41.7 oN vv./
'Note - sedge Emig& wabage for 1 FIE. hive la a rovIalon to prior yem budget templates.
2 Other Allowable Travel r err rental pAlung.
R yan laraJal Pan A aas anle•rr.••e /hid cr,s1s included haw wodein Adownistwaw Coats
OilEr TIline melee. loaqmsd ri t.,../ir,yalanl amour, le•el• ••
06iI ilMN
=AAP_ ltewilew awwwwea
cent
Une item
Cent
Lln Item 7
Cost
L Ina Kern
Revel &me* Trd
11411411111.all I won,
Tram'
!nage Lewiew
k %dna 1,701a
Fle•sed 3/10013
Revloovel 3/12111.3

SUPPLIES Provider Entry lAuto Calculation I Date Prepared
The supplies line itern Is used to budget funds for supplies used In the operations of the Grant.
This category can include general office supplies and program/medical supplies
1 General Office Supplies: (Apply an FT E Ratio front the Budgeted Personnel Page)
Pens, paper, toner and eneral suppl,es tt,sr are 'peed ta run an &Ira
Genseal Office &topes hisfitecie Margined Naga" System Crap sward Primary Medical Care
Artnuat : 74, Arirnin lIDIreel I Torts'
Narirsuva DaempUoniCest Al4raclIrrn shmodology
1
2 3 _ -
: I - I
4 . $
3
TOTAL
-
2 Program Supplies
PrograrniMealcal Supplies are budgeted as flesct frevwc•
trolgratriBrupplass laarleuu4 IntegraLDir Fleahr, Bystegy Ovtoaliaril Primary Aledloal Care
arm Budiet Anrkral. Acfrnir, Oliva Narrative ClascneiloolL74,41 Atiocalson riltmodology
A drnirr Dirant Trrl.i I
SUMMAR'''. I Supp
Supplies
Budget Template
Enamel 3/112013
Revised 311/2013
Reviewed 3/1/2013

EQUIPMENT I Provide. Entry !Auto Calculator Date Prepared: 110..221201
The equipment line item is budgeted for equipment purchased or leased in opntunction with operations of the grant
Refer to your contract terms and conditions for requirements related to equipment purchases
EcluiRmayt lloo &al ratr.epr lejnpatent oleserrTerairm Orepotant Pterrerr Modleel
3
I
3
VInr• pi • Wolof • eet • • • el 'owe • 7' re
mow
-7ROWI
_S; -
Equipment
Budgie Template
Effective 3.1112013
Ravage 311/2013
Referral 31112013

Contractual 11evidei Entry jAuto Calculation
Dols Prepared I 10/22R0131
Use gas form to bun. r for Eu1441 11111 md bOoSSCI labor Ssolon I) and subcontracts f Section 2 in eot indis With operating this
Part A granl.
I. oonsliainotPrOfebalonal Contrast La borICleicat Support
Thu budget category includes payments to outside consultants, temporary eareicas, professional contract labor and derloal support.
indicate iris noise licensesigunliricalions hese tutored, Awed rale, claws of so," arid a ddiai,ad toutal„,..0,61‘,.wn
martin to be provider
li,Conisuitirt/Pirtitessional Contract LaboriCla icel Support Maricopa Integrated Health System Outpatient Primary Macke Care
Coeulliarel Annual Quoted Total , Aerie , Adrroin Dinel Ilevics Cistee or Service
Illo-PV @ledger* env/. Rate Budget i Budget % I Budge' ' Budget
Llcanses f t 3 . 5 - : 5 . — _ _
qualMcatioruLl
Narrattol
Justificallon '
, 4 - 1 .
Lierinea I 1
tpleetkrUons , –,
Narrelval i
Justification 1
r t I . •
Licenua I P
qualifications
Narrative
Justification
4 1 f _ • _ r . _
Licenses _
qualifications ,
Narrative! t
JualificatIon
S • _ I s
Llisioniaa 1
qualifications
Narrative
• -
blame& I
qualification&
Narrative/
Justification
cuisseirien•Cieloal the Part I 1.1rS'L . ,4 71 -
• • PM Cloncni . Frtrn ColVooloi fordnualln. Pulp • W4OrG 1 . 1 1
Subcontruts
rusks only paresis through aubcontrecrla in provide services under lb Ls grant
Each Suboontractor head In ibis asclion *IV it a lob niopiant (not I vendor) must complete a Budget useg the RWPA budget lenient.
Meknes Courly PWPA tell edema fie 10% arinstlatratirs Cont Cop estangshed by HR$A for liranles and refund inn out recipe% entitles mowing Ryan WNW Pert A Purer
I. 51111.117.11a0.1 1 r : Doe nth,. a morn., • IMMO ifl Cl ' rima alaskar. Care
Illutemetiarre Set, ucuiera /reset ii lers Ina To Aar*i
Moore ir. Vendor Bulger eugam Beige It of Wool um... rc' Coriwe
— - - , I 11210:11
Services) —
Provided
Raman'
Justification
— I swum. '
Provide:I
Narrative
Justification
— . &Uri el
Nerving( a)
Provided
Narrative!
Justification
i TOTAL .__
firinuri On net Tien.
Cordreclual
Budge Tarripiala
Effective 311 12013
Rensed 31112013
Raviraral 3,112013

Contractual- Continuation Page
Dale Prepared: 1 01221201311
The Contractual line nen a used for COnSueng and contracting 10 be mixed in conjunction with operations of the grant.
Use this page lo list Consultant/Contract Labor end Clerical Support if there Is Muffs:lent space on the Contractual Page.
ConauIttngWrofuIllorlatact La /Clerical Support
....mum rrwruario.O. 40MGLOC1 Larsnin-ernuai DO OM Mint • • Intl road health 5 tern On ...tent Prim MallasI Cara
Consultant 1•10,,, I Ousted Admin Betas or Soniice
— L. Bird • lied I Rai. Bud er St
I ' S_
License. / .. _
qualifications
Narrative
o! t ' -
Licenses /
qualifications
Narrative
0. $ - 1 ... , 5 .
Licenses I
qualifications
tharraffve
Licensee 1 -
qualifications
Narrative
1 —
01 $ - I .... - 5 _
Licenses 1
qualifications
Karr:adv.
11 01 S -
Licenses / —
• uallflcallons
Narrative
12 I 0: 5 - $ - I 5
Licenses I
qualifications
Narrative
1 € - ! 5 " [1 . IS -
Licenses 1
Qualifications --,..-1
Narrative
14 I El $ 1 i• . r_.
Licenses I
qualifications
Narrative
1 0! S. . $ • i $ .
Licenses 1
qualifications
Narrative
16 I u! $ - [ - . . S .
Licenses i _
qualifications
Narrative
' ' - - r rDTAn - • .
Contractual Continuation
Budget Templatn
Effective 311/2013
Revered 311/2013
Reviewed 31112013

Other Program Support Provider Entry 'Auto Calculation Date Prepared/
Use this form to budget for other support necessary to provide services under this grant. In the Narrative Justification
describe how the program support will be used and also the methodology used to allocate the total or a portion of the total cost
to the grant.
Communications /Telephone/Wankel MeirLCCelra Integrat-o Health Eyslern Outpatient Primary Medical care
Item Amami Narrative/Cost Allocation Methodology
Badgetatt
- :--i- .. -
i - $ - .
1$ - $ , ,
TOTAL 11— - - TOTAL. 1 ...•,, $ - - _
2
14Wert OUlpillfietkt Primary Med.c-al Care
NarrativeiCost Allocation MemodaH>gy
- f - t
$ . --
$ .. .
- -- $ . - d
7 -UN s - I - TOTAL $
3
Postage Maricope Integrated liealln System Outpatient Primary Medical Care
Item Amount NarrativetCost Allocation Methodology
Budgeind
TOTAL
4
Utilities are 100% administrative "an 6.6.B05
lltilnive iikalco a Int *tad limelh 3i1.m dud rem Primary Medical Care
Item Amount Narrative/Cost Allocation Methodology
Budgeted
- i
I S ' i
S . . i
I $ - : !--
TOTAL ...‘ - • TOTAL i I, $ .
Maricope integrated leulth System 43-uipatient Primary Medical Care
NarradvAlLost Alb:Ica:hen Meihodiklogy
khomusl.Sorour W.311 .ra 32,317,221.74 IT.141...M Sem IMEall.131
!t
145-74 --- '
MEM -
.SUMMARY Progtash Support A61 1" - $_
Program Support
Budget Template
Effective 3/1/2013
Revised 3/1/2013
Reviewed 311/2013

urherlororeseionai Service
DM Prepare
Use this Pm to budget Ion Ohre profistainnal services, audio/accounting, Irsureiste. renUagme. of ether' Plofessamoi allinaCee
ArildithROCOURtirielnanCe
11.00. Mir • m Chripinivrri P•ist-iry lieirseal ears
IniLOO1 "C'at , I taend Dan Der Malian avi wk.!,
Name leu•giviteri Fear . 411;;545.
css
Due
turlihallkoa. •
thel Mailit4x
th en
Minus:
-. 6111, 11 E10 149
Cost Method
Lined
Budget
Justification
ToE
2
111M1 re • - len! P "•Ocal. •Im.
-rrilr Amor 13*
blare. R MOM ISERI 'MA si ran
1 f 5 5
CiA5511111411:1
'ULM
f54p5 1
blollhunlin3
1 ' I
Cum! Method
ussil
Badger
Jr-irc•fizartrun
i • I IMEM
Cost Method
Used
7 u, ge
Justification
± ' :.1' ,.1. ,1 1
a Rwat&patir
Rent is considered 100% administrative
4 Other Professional Service
r Msffice _
4=1Pigem of asNice
C.511 Pird11.,1
rh5101
iwalfirJrtiwi
I I.
tc4.1 !island
Juslific ahr.i
76 ).e. •1 - ii - 1S •
AVOM
. SLIMAAFIV :15...I n. 5 • S • ;
Miter Prof Svcs
Budget Template
Effective 3/t,2010
Roland 311/2013
Reviewed 211f2013

(ie etc.) average on that average on that average on that average on that average on
Source Rate, -itietTs3iTt.-- an based 2012-13 (Note an based 2012-13 (Note an based 2012-13 (Note an based 2012-13 an based 2012-13 .
CoobstA1 AHCCCS,11-1S.. R is visit from R is visit from is R visit from re test from (Note is test from .....
Fee Negotiated year). year). R year?. R
Only •ArleaCS. Column per actuals grantyear). AHCCCS. Column per actuais grant AHCCCS. Column per actuate AHCCCS. Column per actuals ANCCCS. Column per actuals granlyear)
Poivabonumnowl fee fee fee grant fee grant fee .
10122120131 Service Per IY • - - - - .
Cost Payment ---- 488,055,32 299,299.32 73.478.00 1.Ms.anso 1128,388,00 2.3V.227-* 2.548.114g05 (231.722.72) dmAltooartwo
for obocovelActivi
Fee Do
RN. Total 11•6no.
S $ S S $ 3 $ $ $ S. S 3
Prepared' Clients Clients Client Fee Product] _ 8819 $ 1 001.00 4244 381.50
ehveraNe /ST „,, 61.61.0
New Proposed 3 Ws*.
Date of Returning Unduplicated Fair D I 1 OmniUnt.-
Toil
Number of Feb Om IT 2
Meesures: of 343
Number e Jan 24.1 241.1 EMI NM , 7
Total awe 7341
Dec Ma I
Performenee Sian
Nov Pm II Me 24; :
MIll J.616
Oct 6441 *0 We
Deliverables 1242
Sep 414:4, f are MIMI i
MIN T.-- 6.641
of Aug IP4 27. Yew SP : -111 1.
Schedule July • :111 47 2 rra- X 1== I , 1 .
643
I *Pe • 3 .
June sin
5.3l.1
May 641 • u. . ...
O5$1.
CaittiatgO System CATO Apr MI I or • . ,
=111011! ±311
Auto Mar 9 ay
Noaeth latoScal MI E 7A3
EEP-Tyl of . 1 i i i • 3
7,128 1,154 24 31.440 380 - 118
lytov.cler inte(freted Prtmary Number Units Proposed 411
31.11e0PA Oatesbent Unit . nuntlel) WI diaramin
Definrtion unit viet WA vist WI
SerAce 1 16 1 t •
(to. tweet ural•1 unk ii.yrreari re
I 1 i Wel
Description sotestere euesetera can
/mewl sisow,
arirmyrnesiniem Lerweeelreptiosl_
Deliverables Sopece drisivait ece.re.leas speetady del OutPrOsal tP4nroirmliving
Name. Fee.-1 cake ree
of Category Unit SWAM &Mow savor Deliverables
Organizaeon C.AREWare NamelCode
Service Service libidial Sane*, Sammy TOTAL Template 31112013 3/112013 311/2013
Schedule . , of
--s-- I 2 3 g e e Ii q IIA 14 151 Schedule Effecave Reviewed
Budget Revised

Attachment 2-C
Maricopa Integrated Health System
Ryan White Part A Services — Outpatient Ambulatory Medical Care Service
Solicitation 13126-RFP
Introduction:
For more than 20 years, Maricopa Integrated Health System (MIHS) has provided state-of-the-
art care for Persons Living with HIV/AIDS (PLWHA) at the McDowell Healthcare Center.
Dedicated to serving PLWHA, the McDowell Healthcare Center (MHCC) is a comprehensive
HIV clinic that offers outpatient ambulatory medical care, OB/GYN, outpatient mental health,
outpatient substance abuse service, oral health care, laboratory testing services and early
intervention services. As the largest provider ofHIV primary care services in Maricopa
County, one in every three PLWHA in care in Maricopa County chooses to receive all or part
of their health care at MHCC. Because of the excellent reputation of MI-ICC in the state, and
lack of providers in rural areas, patients from other geographic areas of the state seek HIV
outpatient ambulatory medical care services at MHCC. MI-ICC is also home to the only HIV
Women's Clinic in Arizona. In June 2011, the Arizona Board of Regents unanimously approved
an affiliation agreement between MIHS and the University of Arizona — Phoenix (U of A
Phoenix). This agreement allows MIHS to become the primary training, research and education
facility for the ll of A Phoenix College of Medicine and enhance our system.
1. Ability to imorove accessibility of Ryan White funded services.
MIHS is the logical and appropriate choice to be a RWPA grantee for this comprehensive,
coordinated, and culturally competent system of Outpatient Ambulatory Medical Care (OAMC).
MIHS is the grantee for Part C and Part D, the main medical and oral health care provider for
Part A administered by Maricopa County, and a close partner with Part B. All of these services
are provided in one clinic that allows for a full continuum of care. To show its strong
commitment to PLWHA, in 1990, MIHS dedicated one of its 11 outpatient clinics to address the
medical, behavioral and oral health needs of PLWHA. That clinic is the McDowell Healthcare
Center.
MIHS — First Ryan White Grantee in Arizona. MIHS has been actively involved in Ryan White
Programs since 1991 when MIHS received the first Ryan White grant (under Part C) in Arizona.
As Arizona's largest public health system, M1HS has the capability and experience to respond to
PLWHA. MIHS has served as the largest healthcare safety net for Maricopa County residents for
over 135 years. Organizational strengths stem from a comprehensive healthcare delivery system
incorporating the Maricopa Medical Center (MMC), a 449-bed public teaching hospital with a
Level I Trauma Center; the Arizona Bum Center; two psychiatric facilities housing 189 beds for
behavioral health services; the Comprehensive Healthcare Center offering outpatient primary and
specialty care; and 11 outpatient Family Health Centers (FHCs), including the comprehensive
McDowell Healthcare Center. MIHS is the largest provider of comprehensive and coordinated
HIV-related OAMC for adults in Maricopa County, and serves the greatest percentage of
minority individuals in Maricopa County receiving HIV care. MHCC created the only
HIV/AIDS Dental Clinic in Arizona in 2000 focused exclusively on PLWHA, and additionally
provides psychiatric, mental health and substance abuse services focused on HIV care.
Experts in HIV Disease. The McDowell Healthcare Center (MHCC) is recognized as the center
for excellence in HIV care in Maricopa County and is the largest safety net provider offering
state-of-the-art HIV medical care for adults. MIHS' vast experience includes:
Page 1 of 14

Maricopa integrated Health System
Ryan White Part A Services — Outpatient Ambulatory Medical Care Service
Solicitation 13126-RFP
• The MHCC provides a significant proportion of the HIV care in the region, serving one in
every three PLWHA in Maricopa County, with the majority being underserved, ethnically
diverse and medically needy individuals;
• MIHS provides the only comprehensive and seamless continuum of care for adult PLWHA
including OAMC, a Women's HIV Clinic, treatment adherence, mental health, substance
abuse services, oral health care and early intervention services in one location;
• MHCC has the ability to refer to specialties, sub-specialties, support services and inpatient
services, and has full access to information through the system-wide Electronic Medical
Record (EMR);
• MHCC participated in HIVQUAL-US between 2004 and the 2011 review periods. Our
results repeatedly showed that on a national level, we consistently provided PLWHA with
high-quality, cost-effective medical care;
• MIHS is home to the largest teaching hospital in Maricopa County, providing medical
residents with an HIV rotation at MHCC that trains future physicians for this and other
communities regarding care for PLWHA;
• MIHS, as both a teaching hospital and an affiliate of the U of A College of Medicine and
District Medical Group, supports and encourages patient referrals to and participation in
clinical trials within and outside our system;
• Four MHCC clinicians, two physicians and two nurse practitioners have each been
providing full-time HIV-specialty medical care since the 1980's. All are certified HIV
specialists through the American Academy of HIV Medicine;
• Dr. John Post, the MHCC founder, has received numerous awards over many years for his
comprehensive and compassionate care, including the 2011 Phoenix Business Journal
Health Care Heroes Award;
• Dr. Ann Khalsa, MHCC's Medical Director, is a nationally recognized HIV specialist and
educator. She has been involved with the Ryan White AIDS Education and Training
Center program since 1990, providing direct full-time clinical preceptorships in HIV for 15
of those years. She received international recognition at the International AIDS Conference
in Mexico City as one of fifteen recipients of the U.S.-Mexico Border Hero Award;
• MIHS has an excellent reputation in the medical community as a provider of quality
HIV/AIDS treatment and services, from dedicated and knowledgeable clinicians. This is
reflected in the significant increase in the number of PLWHA we serve. MHCC provided
care to 2,906 PLWHA in CY2012, an increase of 11% from CY2011;
• MIHS and MHCC provide culturally sensitive and accessible care. Three of the clinicians
are bilingual in Spanish and on-site translation is always available utilizing bilingual clinic
support staff. MIHS utilizes the telephonic World Wide Interpreter service, through which
communication is possible with our many refugee immigrant patients from locations such
as Burma and African nations. The MHCC clinic has a program of Cultural Health
Navigators who provide an additional layer of patient support and education;
• MIHS has stellar fmancial systems in place to report and track administrative and clinical
data through the EMR; and
• Women can schedule an appointment with either an OB/GYN physician or Certified Mid-
Wife at MHCC during Women's Clinic. This eases transportation concerns and encourages
them to keep appointments, access services and/or address related issues.
Page 2 of 1.4

maricopa Integrated Health System
Ryan White Part A Services— Outpatient Ambulatory Medical Care Service
Solicitation 13126-RFP
Rapid Testing in 17 Labor & Delivery (L&D) Hospitals and MIHS Family Health Centers.
In July 2005, the MIHS RWPD program launched an initiative to ensure that all pregnant women
at all MIHS facilities receive a rapid HIV test during routine pre-natal care. Additionally, if a
woman presents to Maricopa Medical Center (MMC) during labor and has not received pre-natal
care or does not have a documented pre-natal HIV test in her medical record or was at additional
exposure risk since the initial test, she receives a rapid HIV test during labor and delivery. In
2010, 100% of women with pre-natal care and 96% of women with no pre-natal care or no
documented HIV test received a rapid HIV test in the L&D unit. Since this program was
instituted, there has not been one HIV-positive baby born at MMC. Due to the success of the
L&D initiative at MMC, RWPD expanded the initiative to other L&D units in the service area.
As a direct result of the support and technical assistance provided by the MIHS RWPD program,
16 additional L&D units in Maricopa County now offer HIV testing during pre-natal and pen-
natal care. Including MMC, this represents 81% of all L&D units in Maricopa County.
First Arizona Hospital to Offer Rapid Testing in the Emergency Department (ED). The Adult
ED at MIHS' Maricopa Medical Center (MMC) received a grant in partnership with the Arizona
Department of Health Services (ADHS) through the Center for Disease Control and Prevention
(CDC) to begin confidential, routine opt-out HIV rapid testing in 2011. The goal of the project is
to test individuals who seek medical care at the ED. This program, known as TESTAZ, provides
the opportunities to: 1) link patients who test HIV-positive earlier into HIV medical care and
support services as early as possible, and 2) link patients who have fallen out-of-care back into
medical care and/or support services. Newly diagnosed individuals are provided information
regarding modes of HIV transmission and prevention. In the first two years, through TESTAZ
nearly 18,000 unduplicated individuals were tested for HIV. Of those tested, and as of
07107/2013, fifty-six (56) previously undiagnosed patients were confirmed HIV-positive. This is
a positivity rate of 0.28%. Due in part to funding available through Part A, forty-three (43 or
76.8%) of the 56 patients have been linked to HIV medical care. We anticipate that routine opt-
out testing in the ED will become the standard of care throughout Maricopa County hospitals,
thus enabling the early identification of HIV-positive individuals who present at the ED.
MIMS On-line Training. MIHS mandates training for all relevant staff pertaining to HIV testing
through our on-line learning management system. The purpose of this training is to assist
employees and providers to have informed conversations with patients who are or may be HIV-
positive. The training is divided into three learning activities that include: 1) an overview of
HIV; 2) the rationale, benefits and procedures for routine opt-out HIV testing; and 3) the details
about how routine, opt-out HIV testing has been implemented in our Adult ED. A demonstrated
100% competency is required upon post-test.
Providing Services Throughout the EMA. MIHS will provide OAMC in all seven of the
identified RWPA Planning and Service Areas. The Phoenix EMA (Maricopa and Phial counties)
encompasses over 66 percent of the state's population. ADHS reports 15,288 PLWHA
(September 2013) in Arizona, with 75% of those residing in this service area. ADHS has
identified downtown Phoenix and those living within a ten-mile radius as the highest risk area in
Arizona, where the majority of the state's HIV/AIDS infected (1 in every 3) and at-risk
populations reside. Based on this demographic data, MEICC recently joined with the Parsons
Center for Health and Wellness (aka The Southwest Center for HIV/AIDS) to create a
strategically located, one-stop vibrant community health center in the heart of this at-risk
Page 3 of 14

Maricopa Integrated Health System
Ryan White Part A Services— Outpatient Ambulatory Medical Care Service
Solicitation 13126-RFP
geographic service area. MHCC occupies 10,000 square feet of this center and provides OAMC,
oral health, substance abuse services, treatment adherence, education, mental health, a HIV
women's clinic, early intervention services, and other services for PLWHA. The center is located
on the light rail and within walking distance of bus stops, allowing for ease of access to co-
located services. A grand opening for the center occurred on November 1, 2013, We are
confident that the on-going co-location of services will help reduce disparities and strengthen
M1HS capacity to deliver HIV healthcare and chronic disease support.
Medical Care and Assessment. MIHS provides a comprehensive, coordinated, culturally
competent and family-centered system of care for PLWHA, consistent with Public Health
Service guidelines. Initial status for new clients is assessed through a comprehensive evaluation
including patient medical and psychosocial history, family history, mental health and substance
abuse evaluation, physical exam and diagnostic laboratory testing. The tests include, but are not
limited to:
• CBC with differential • RPR or Syphilis 1gC
• Metabolic Panel • Hepatitis A, B and C
• Cholesterol & Triglycerides • TB exposure and immunization status
• HIV-RNA & CD4 Panel
MIHS Electronic Medical Record (EMR) System. MHCC utilizes a robust, integrated EMR
called EPIC for referrals across MIHS. By utilizing one design with best practice customization,
referrals are supported with efficient and effective communication between internal and external
providers for hospitalization, subspecialty medical services, and/or social services. The primary
medical providers order referrals daily depending on patient need. Patient and provider
communication, and agreement on the referral, support patient compliance and follow-through.
EPIC allows for the identification, documentation and discussion among the care team of a
patient's refusal for tests and/or of barriers to care such as scheduling issues. EPIC is a valuable
tool for referrals by ensuring regulatory compliance and communication between providers,
enhancing appointment scheduling of the referrals and follow-up regarding the referral results.
The clinician can flag the referral for acuity level and specify time frames for potentially
emergent situations or order changes as needed. Standardized workflows at MHCC are entered
into EPIC at the point of care. Each result is attached to the corresponding order.
Outpatient mental health and substance abuse screening, assessment and treatment services.
MIICC is a licensed Outpatient Behavioral Health Clinic through the ADHS Office of
Behavioral Health Licensure. The primary care and mental health clinicians work collaboratively
toward the goal of total patient well-being. This integrated relationship assures early intervention
in medical and mental health issues and eliminates potential barriers to the referral process.
Complex co-morbid medical and psychiatric conditions are addressed including problems with
poly-pharmacy and drug-to-drug interactions. Mental health patients receive counseling and
therapy for HIV-specific issues, addressing social and internalized stigma, chronic illness and
pain, grief and end of life issues, as well as substance abuse, depression, anxiety, psychosis,
domestic violence, dementia, sexuality and gender issues, family dysfunction and stress
management. For those patients needing substance abuse treatment, there are numerous referral
resources off-site in greater Phoenix including detox centers, residential programs and out-
patient services.
Page 4 of 14

Maricopa Integrated Health System
Ryan White Part A Services — Outpatient Ambulatory Medical Care Service
Solicitation 13126-RFP
Oral Health Care. The MHCC dental program has become a teaching model for other dental
clinics. Because dental services are provided on-site at MHCC, there is a healthy professional
relationship between medical and dental providers. This closeness has allowed for educational
opportunities, easier accessibility of consultation and access to relevant information on both
sides. There is full integration of care for shared patients which has led to assimilation of
treatment planning and a broader awareness of the patient's overall health.
In+Care Campaign. The Health Resources and Services Administration (HRSA) HIV/AIDS
Bureau together with the National Quality Center (NQC) have teamed up on a national retention
campaign where clinics can have an immediate impact over the health and well-being of HIV
patients. The goal of the campaign is to bring patients back to care and keep others from falling
out of care, leading to healthier people and stronger communities. MIHS has developed
committees for each of the 4 In+Care measures through our HIV Quality Committee at MIICC.
We will submit our first round of data in December 2013 which will include information on the
total patient cohort at MHCC.
Medical Case Management (MCM). MCM ensures continuity of care for all patients and their
families so as to receive the medical care they need to stay healthy. All members of the network
are aware of the vital link between support services and medical services. Many patients lead
extremely challenging lives: many have multiple problems that are as important to their
continued well-being as care of their HIV disease. These include care giving, lack of health care,
poor health status, lack of basic resources such as housing and food, lack of education and
literacy, and unfamiliarity with preventive medical care. Each patient's complete needs must be
addressed including adding care of HIV disease to their everyday life. MCM assists the patient to
access care: this is the link between support services and medical services. Ryan White Part D
MCM services are co-located at MIICC.
On-going Treatment. Patients are routinely seen three- to four-times annually, or as often as
needed, for on-going immune surveillance, management of HAART and monitoring for related
opportunistic complications and co-morbidities. M1HS, including MHCC, has adopted the
national Patient-Centered Medical Home Model approach to clinical care. MHCC actively
participates in patient-focused continuity of care with attention to best practices for chronic
conditions such as HIV, diabetes and hypertension. Since primary HIV care includes a focus on
long-term prevention of complications, MHCC clinicians have been providing continuity-
provider care with focus on periodic preventative health assessments and co-morbidity
monitoring and management. Patients are involved in their medical decision-making as the
primary member of the health care team.
Clinical Trials. Patients at MHCC are informed about the availability of clinical trials through
their MCMs and HIV clinicians. Patients are given resources detailing available local trials.
Once the primary care provider meets with the patient, and the patient expresses an interest in
participating in research, an evaluation is completed to determine whether the patient is qualified
to participate in a research study. Providers are well trained and informed about the available
trials and serve as the patient's link to a clinical trials program. Patients may be referred to both
local and national research opportunities, including the current National Institutes of Health trial
on long term non-progressors. MHCC has initiated clinical trials and our collaborations include
universities, research institutes and healthcare providers. Community alliance initiatives are
Page 5 of 14

Maricopa integrated Health System
Ryan White Part A Services — Outpatient Ambulatory Medical Care Service
Solicitation 13126-RFP
focused on increasing participation in prevention programs by underserved populations including
those from minority communities.
Laboratory Services. Laboratory services are provided by the Maricopa Medical Center (MMC)
laboratory which is CAP, CLIA, and DNV accredited. The greatest number of laboratory tests,
including CD4 panels, viral load levels and HIV genotypes, are conducted on-site at MMC. The
State, through its Communicable Disease Prevention and Surveillance Program, covers the costs
for confirmatory HIV testing for Ryan White Part C funded rapid tests conducted at the
Southwest Center. For those patients with insurance, two other local laboratories are available
through contractual arrangements with the individual insurance provider agencies.
Pharmacy Assistance Programs. For uninsured patients, pharmaceutical services are provided
through Avela, the ADAP contracted pharmacy. Medications not covered by ADAP can be filled
at the MMC Outpatient Pharmacy, located on the MMC campus (less than 2 miles from Avela)
or at outside commercial pharmacies. The MIHS pharmacy receives 340B pricing. For those
with health insurance, patients are referred to the appropriate contracted pharmacy. Ryan White
MCMs and clinicians assist patients to access pharmaceutical company Patient Assistance
Programs.
Weekend and After-hours Coverage. MIHS policy provides patients the opportunity to obtain
after-hours care through an answering service at MHCC. The procedure is:
• The main phone numbers automatically roll over to the answering service at the end of the
business day.
• An automated voice mail message in English and Spanish alerts the patient that the clinic is
closed and gives the patient the option to speak with an operator. The message includes the
clinic name, hours of operation and emergency referral information.
• At the patient's request, the answering service will page the on call clinician with the patient
contact information. The clinician then contacts the patient and conducts an assessment.
• The clinician documents the encounter in the EMR which is forward to the patient's primary
care provider.
• If the patient is pregnant, all after-hours calls are forwarded to the MMC L&D unit and the
attending physician assesses and documents the patient's health.
MHCC patients have the option of visiting the centrally-located MIHS 7 th Avenue Walk-in
Clinic for care after hours and on weekends. This clinic is open every day from 7am — llpm and
has access to all MHCC patient records through the EMR.
Referrals for H1V-Positive Patients. MEICC provides referrals to specialty and subspecialty
services offered primarily at MIHS' Comprehensive Healthcare Center (CHC) located on the
MNIC campus. Specialties and subspecialties include, but are not limited to the cardio-
pulmonary clinic, dialysis, ENT clinic, oncology, ophthalmology, radiology, outpatient surgery
clinic, and the Refugee Women's Health Center. Women needed referrals from MHCC for
enhance OB/GYN services are referred to the Women's Health Center, the Refugee Women's
Health Center, the Teen Pregnancy Program, or the Internatal Clinic. All are located at the CHC,
which is also home to the Phoenix Cancer Center.
Page 6 of 14

Maricopa Integrated Health System
Ryan White Part A Services —Outpatient Ambulatory Medical Care Service
Solicitation 13126-RFP
Tobacco Cessation and Condom Distribution. Tobacco cessation assessment and intervention is
repeatedly offered, with linkage to appropriate tobacco cessation resources including the Arizona
Smokers' Helpline and patient assistance pharmaceutical programs when needed. Sexual activity
is assessed and safer practices are encouraged using the Prevention for Positives model with both
harm and benefit framed messages. Additionally, to reduce risky sexual activity, condoms are
available on-site at MHCC. After Visit Summaries (AVS) printed for patients after medical visits
also contain prevention messages.
Assistance with Eligibility. A full-time bilingual in Spanish Eligibility Specialist (ES) is
available on-site at MHCC. The ES conducts financial counseling interviews with patients to
establish eligibility for programs. The ES is responsible for pre-screening all uninsured clients
for AHCCCS (Medicaid) eligibility, assists patients with enrollment into the appropriate benefit
program, and refers patients to financial assistance agencies. This eligibility assistance extends to
the expanded Medicaid program approved by the Arizona Legislature earlier this year.
Individuals who are otherwise qualified but are over income for Medicaid are referred within
MIHS for assistance with Marketplace enrollment.
2. Ability to deliver services to the Phoenix EMA's special populations.
MIHS is committed to addressing the service needs of individuals who know their HIV status
and may not be receiving primary medical care services. We are dedicated to informing and
enabling individuals to utilize services. Our overarching goal is to eliminate disparities in access
and services among the underserved. MIHS addresses these service needs based on these four
guiding principles:
1. The HIV/AIDS epidemic is growing among traditionally underserved and hard-to-reach
populations. MIHS serves a high percentage of PLWHA who are ethnically diverse
(Table 1), are uninsured and/or live below 100% FPI-
2. The quality of HIV/AIDS therapies can make a tremendous difference in the lives of
PLWHA. The MHCC 2011 HIVQUAL review showed that 97.1% of all patients eligible
for ARV therapy are taking medications to fight HW.
3. Changes in the economics of health care are affecting the HIV/AIDS care network. MIHS
is working with RWPA and RWPB to enroll individuals into expanded Medicaid and the
healthcare marketplace; and
4. Outcomes are a critical component of program performance. MIHS believes evaluating
outcomes is critical to measuring program performance, and has demonstrated its
commitment to program performance by being involved in HIVQUAL-US between the
2004 and 2011 review periods.
Target Populations and Diversity of PLWHA. MHCC provides services to a PLWHA
population that is highly diverse. Our target populations are primarily non-White minorities
(54.8%), Hispanics (30.1%), males (80.1%) and women (19.9%). Included in these target
populations are individuals that are uninsured, those living below the Federal Poverty Level
(FPL), resettled refugees and those of other language groups. As shown in Table 1, there are a
number of similarities among the populations of the U.S., Arizona, the Phoenix EMA. and
MHCC patients. However, MHCC exceeds the national norm for the number of minorities
served. While the U.S. population is 16.3% Hispanic, Arizona's population is 29.6% Hispanic.
Page 7 of 14

Maricopa Integrated Health System
Ryan White Part A Services - Outpatient Ambulatory Medical Care Service
Solicitation 13126-REP
Hispanics account for 18.9% of PLWHA in the U.S., but are 26.1% of PLWHA in the EMA and
30.1% of all MHCC patients. While Arizona has a relatively small population of Blacks at 3.7%,
they comprise 18.5% of MHCC patients and over 36.5% of Part D patients. On average,
minorities account for 54.8% of all MHCC patients.
Table 1. Race and ethnicity of target population compared to national, state, and local populations,
2010 U.S. 2010 Arizona 2010 2008 U.S. 2012 Ph 2 oenix 012 MI- 2012 a
Populcrtionl Population' Ph oenix PI.WhIA: Arizona BAA Patiente
EWO PLVVI-IA 3
NAHA)
NOT
HISPANIC:
White 831% 57.8% 58.7% 33.8% 55.8% 55.5% 45.2%
Black' 12.2% 3.7% 4.6% 43.9% 11.8% 13.0% 18,5%
AVAN" 03% 4.0% 1.9% 0.4% 3.5% 2.5% 0.9%
Asian 4.7% 2_7% 3.2% 1.1% 1.4% 1.4% 2.1%
NH/OPI"' 0-2% 0.2% 0.2% 0.1% _ _,----f: OA
. Multiple races 1.9% 1.8% 1.9% --.-----___ 11% 1.6% 1.5%
OtherNnknown 02% 0.1% 0.1% - -- - I--. .-------- 32%
HISPANIC: 16.9% 25.9% 26.1% 30.1%
Vine 14.5% 28.8% 29.13% __ - ---__„------- _....„..------
„ Black' 0.0% 0.7% 0.7% ,.-- __-- --- ______ ,--
A VAN" 0.3% 0.7% 0.6% _-------- ---- ___----
Asian 0.1% 0.2% 0.2% ,-------- .......-- ------ N. Ili
NH/OPr" am 0.1% 0.1% ,--- - - -- Mill
Multi , le races _ 0.2% 0.4% 04% ...------ ---- 'Mill
Other/Unknown ____----- ----- _____..-- ______------ _ _-- _.
.63ack or Africar. -Arnerraan; "American Indian 8 Alaska Native; "'Native Hawaiian & Other Pacific Islander; 1Population
estimates from the U.S. Census Bureau, American Fact Finder; 2 Centers for Disease Control and Prevention, February 2013;
Hispanic is not broken down by race; 3 Estimates from the Arizona Department of Health Services, HIV Statistics Annual Report,
2013; 'Native Hawaiian and Other Pacific Islander included with "Asian."Hispanie is not broken down by race; 4 MIHS System
Inter!, ai Rq,<-:ns
Eliminate Disparities in Care in Communities of Color. Rates of HIV/AIDS prevalence and
emergence differ sharply between African Americans and other race/ethnicity groups. The
emergent HIV/AIDS rate among African Americans in Arizona is more than double that of any
other race/ethnic group and 164% higher than the statewide average. The disparity is more
pronounced among African American women than men. Although HIV has historically been a
disease that predominantly affects males in Arizona, the 2012 HIV prevalence rate among
African American women at 418.28 per 100,000 population was 5.7% higher than the next
highest HIV prevalence rate of 73.35 per 100,000 population among American Indian women
(2012 HIV by Race/Ethnicity, ADHS). MIHS has an extensive history in serving communities of
color in order to eliminate disparities in HIV care. For example and as shown in Table 1, while
Blacks account for only 4.6% of the population in the Phoenix EMA, they comprised 18.5% of
MHCC patients in 2012.
Exposure. As shown in Table 2, there are several differences pertaining to exposure among
PLWHA in Arizona, the EMA and MHCC. MSM is the most commonly reported transmission
Page 8 of 14

Maricopa Integrated Health System
Ryan White Part A Services — Outpatient Ambulatory Medical Care Service
Solicitation 13126-RFP
category across all groupings. There was substantially less exposure for IOU for PLWHA in Part
C. Heterosexual transmission accounts for over one-fourth of all PWLHA in the U.S. However,
for RWPC, the rate of heterosexual transmission, at 34.1%, is more than three times the rate for
the state, service area and EMA. Significant proportions of heterosexually exposed patients live
below the FPL and/or are uninsured. Although they have other health care options, these patients
choose the MIHS program.
Table 2. Exposure category of target population compared to national,
stale, and lo-cal populations.
2010 U.S. 2012 2012 Service Phoenix 2012 2012 MIHS
PL.WHA , PLWHA2 Arizona PLWHA2 Area EMA RWPC2
PLIAMA1
Men who have Sex with Men (MSM) _ !..c.21 - 50.0% 50.7% 61.2% 52.9%
Intravenous Drug Use (IDUI 1 ," • 10.4% 10.5% 9.7% 5.8%
MSM and IOU . Fl. 8,5% 8.6% 82% 8.7%
Heterosexual Contact :',.'. l , 10.8% 9.8% 10.3% -, 32.0%
Other* ' '.':.. 10.2% 10.4% 10.5% 0,6%
"Other includes hemophilia, blood transfusion, perinatal exposure, transplant reclprent, and unknown or not identified risk,
ICenters for Disease Control and Prevention, HIV Surveillance Report, February 2013; 2Estimates from the Arizona Department
of Health Services, HIV Statistics Annual Report, 2013; 3Maricopa Integrated Health System Internal Reports
Serving a High Percentage of Women. MHCC continues to see increases in the number of
minorities impacted by HIV/AIDS, especially among female minorities. A goal of MIHS is to
increase access to OAMC, mental health, substance abuse services and dental care especially for
minority females. To address this goal, MHCC established a Women's Clinic on-site staffed by
OB/GYN providers. Women's Clinic includes breakfast, women's support groups featuring
educational seminars and on-site childcare in collaboration with the Southwest Center for
HIV/AIDS. As a result, the number of women clients at MHCC has steadily increased from 250
in 2004 to 577 in 2012, an increase of 131%.
High Levels of Uninsurance. Reports from the U.S. Census Bureau in 2011 show 19.1 percent
of Arizona's population lacked health coverage, with about one in five residents lacking health
coverage. Census data also show that 1 in 5 uninsured Americans reside in only 13 counties. To
put that in context, there are more than 3,000 counties in the U.S. Maricopa County, Arizona,
ranks sixth on that list. Only 8.7% of MHCC patients had private health insurance in 2012. The
remaining 91.3% were enrolled in Medicare, Medicaid, PC1P, Ryan White or paid out-of-pocket
for their care.
Individuals Who Live Below the FPL. Data from the U.S. Census Bureau show that 18.7% of
Arizonans and 17.5% of Maricopa County residents live in poverty. Maricopa County also has a
sizeable per income gap for residents of Hispanic/Latino origin compared to the population as a
whole. For all residents of Maricopa County, annual per capita income is $26,406. For Hispanic
residents of Maricopa County, however, annual per capita income is $13,636. This is just barely
half. Sadly, more than 60% of all MHCC patients live below 100% FPL.
Refugee Resettlement Data from the Office of Refugee Resettlement shows that Arizona ranked
ninth in the nation for new refugee arrivals in FY12. Nearly 80 percent of all resettled refugees
are women and children. Seventy-six percent of refugees resettle in Maricopa County and, of
Page 9 of 14

Maricopa integrated Health System
Ryan White Part A Services — Outpatient Ambulatory Medical Care Service
Solicitation 13126-RFP
those, 66 percent reside in Central Phoenix where MFICC is located. A large percentage of
immigrants and resettled refugees have come from Somalia, Burundi and, more recently, Burma.
MIICC continues its history of providing culturally and linguistically competent care to all
patients, as discussed in this application.
Other Language Groups. The U.S. Census Bureau Hispanic Population 2010 report states that
Arizona ranks fourth highest in the nation with a Hispanic/Latino population. Nearly 28 percent
of the state's population five years and older speak a language other than English at home. A
recent University of Arizona Mexican-American Studies and Research Center report found that
Hispanic women living in Border States have a higher risk of contracting HIV than do other
Hispanic women due to their lack of knowledge of HIV/AIDS.
3. Ability to provide culturally and linguistically appropriate HIV/AIDS services.
Culturally and Linguistically Appropriate Services (CLAS). MIHS primarily serves patients
who speak English, Spanish and several African languages; however, the predominant non-
English language spoken by our patients is Spanish. The literacy levels of our patients can vary
greatly. Even when we meet the language needs of patients the level of literacy must be
considered. MIHS makes every effort to provide patient materials, including Spanish
translations, at a 6th grade reading level or lower. MIHS meets the enhanced National CLAS
Standards by providing our patients with translation and interpreting services. As mentioned,
many of the MHCC staff and clinicians are bilingual in Spanish. For non-Spanish speaking
patients and/or those with limited English skills, staff has access to real-time translation utilizing
the phone-based World Wide Interpreters service that is available throughout MIHS including
MHCC. Through an MAT-funded early intervention services contract, MIHS has contracted for
two Cultural Patient Navigators (CHNs) who are well-known and respected in their
communities. Their primary responsibilities include linking newly diagnosed refugees to medical
care at MHCC, and helping HIV-positive refugees remain in and/or return to care. The CHNs are
fluent in ten languages including English, Liberian, Va, Khran, Swahili, French, Kirundi,
Kinyanvanda, Lingala and Spanish.
We strive to schedule patients with the same provider to provide clinical consistency, thereby
reinforcing trust and respect. Immigrants and refugees are afforded additional privacy measures
beyond the usual and customary privacy practices, depending on their needs and beliefs. Care is
taken to protect privacy and to meet their needs while being respectful of their cultural and social
beliefs. Every attempt is made to work within appropriate boundaries, to sensitively discuss
health topics with the patient, and perhaps most importantly, to instill a relationship of trust.
Cultural Competency Training. All staff make every effort to understand an individual's
cultural beliefs and practices and bow they differ from or reflect the cultural groups with which
the person identifies. To facilitate efforts to understand the unique cultural beliefs and practices
of our patients, cultural competency training is a mandatory requirement for all MIHS clinical
and support staff. In additional to this being a DNV accreditation requirement, MIHS believes
that training of this nature is an integral component of the skill set required for every employee
and clinician. Cultural competency awareness training includes: 1) an on-line curriculum that
discusses important considerations and questions to ask when working with patients of diverse
backgrounds, and requires a demonstrated 100% proficiency on post-test; 2) an employee
orientation session on cultural diversity; and 3) a clinical orientation session on health literacy. A
Page 10 of 14

Marlcopa Integrated Health System
Ryan White Part A Services — Outpatient Ambulatory Medical Care Service
Solicitation 13126-RFP
variety of methods are used to provide this training, including on-site training from experts in the
field. Fulfilling these requirements is part of MIHS employee's annual skills list and
performance evaluations. As MIHS' patient populations change, the focus of the cultural
competency training sessions changes to reflect the demographic changes of MHCC patients.
The MIHS Community Relations Director provides guidance to the MHCC in the area of
language and cultural competency.
MIHS Recognized for CLAS. MIHS has been recognized locally and nationally as a leader in
the provision of CLAS services to patients. The MIHS Community Relations Director is
responsible for directing the language and cultural competence program. Listed below are some
of our accomplishments:
• MIT-IS received no deficiencies from the Arizona Medicaid Cultural and Linguistic
Competent Care team;
• In 2004, MIHS was part of a leadership team for the Arizona Hispanic Center for Excellence.
This project was awarded $1.5 million from HRSA to improve Latino healthcare;
• Cultural Competence Works, Multicultural program Certificate of Recognition HRSA, 2000
and HRSA Publication, 2001;
• Community Centered Health Care Certificate of Recognition, American Hospital
Association, 2000;
• Culturally Sensitive Care Committee, Achievement Award, NACo, 1998;
• Spanish Interpreter Pilot Program, NACo Award, 1995; and
• Spanish Language Training for Patient Care, NACo Award, 1993.
The Health Resources and Services Administration (HRSA) envisions optimal health for all,
supported by a health care system that assures access to comprehensive, culturally competent,
quality care. To further these aims, the Department of Health and Human Services (HHS) has
promulgated a set of standards that define best practices for the provision of culturally and
linguistically appropriate care. In Table 3, each of the enhanced National CLAS Standards is
addressed individually to show how MIHS support the goals of culturally and linguistically
appropriate services. MHCC follows these same principals.
Table 3. CLAS Standards and Addressing by WHS.
Standard Addressed by MIHS
Standard 1: Health care organizations should Both MIHS and MHCC take care to ensure that all patients receive health
provide effective, respectful, and quality care and care that is respectful of the cultural health beliefs and preferred language
services that we responsive to diverse cultural of the patient. For example, with some HIV-positive refugee women, their
health beefs and practices, preferred languages, cultural and religious beliefs do not allow a pelvic examination by male
health literacy, and other communication needs. clinicians. To address this and other issues, MHCC instituted a weekly
day-long Women's Clinic during HIV-positive women are provided medical
care by women clinicians and providers.
Standard 2 Health care organizations should Currently, approximately 50% of MHCC staff members are ethnic or racial
advance aid sustain governance and leadership minorities. This is only slightly less than the proportion of racial and ethnic
loaf promotes CLAS and health equity. minorities (52%) who comprise MHCC patients in 2011. Every effort is
made to ensure a diverse staff that is reflective of the patients served at the
clinic.
Standaid 3: Health care organizations should In accordance with HHS/FIRSA and DNV standards, among others, all
;ecruil. promoter arid support a diverse MIHS employees (about 4,000 individuals) are required to take classes
governance, •eadersirp, and workforce. concerning, among other topics, both Cultural Diversity and HIV/AIDS.
Page 11. of 14

iVlaricopa Integrated Health System
Ryan White Part A Services — Outpatient Ambulatory Medical Care Service
Solicitation 13126-RFP
Standard Addressed by MIHS
Standard 4: Health care organizations should MIHS has a commitment to provide medical care to all patients, regardless
educate and train governance, leadership, and of which languages are spoken. In 2011, requests at MHCC for language
workforce in CLAS. interpretation included Spanish, French, Arabic, Vietnamese, other
(including several African Languages) and American Sign Language.
Interpretation was provided by certified staff interpreters, Cultural Health
Navigators, or a contracted interpreting service.
Standard 5: Health care organizations must offer It is standard practice at MIHS and MHCC that all information concerning
communication and language assistance. language assistance services is available in both English and Spanish. In
house translators are used to translate documents or, in the alternative, to
approve translations from other organizations. M1HS maintains a contract
with an outside provider to provide translations into languages other than
Spanish. CHNs link refugees into medical care and/or remain in care.
Standard 6: Health care organizations must All MIHS personnel who use a language other than English to
inform individuals of the availability of language communicate with patients and their families will be tested for competence
assistance. in that language. If a patient requests that a family member or friend act as
interpreter, a certified medical interpreter will also be present to ensure
effective and accurate communication to the patient. MIHS provides
Language Interpretation Services Anywhere (LISA) for patients needing
additional language services. _
Standard 7: Health care organizations must At both MIHS and MHCC, the most commonly encountered language
ensure the competence of individuals providing outside English is Spanish. As with Standard 5, all signage posted in any
language assistance. MINS facility is posted in both English and Spanish. _
Standard 8: Health care organizations must MIHS system-wide policy #01750 S provides the outline for the MIHS
provide easy-to-understand materials and program of language and cultural competence. The MINS Director of the
signage. Community Relations Department is responsible for the overall
implementation and monitoring of the language and cultural competency
program :
Standard 9: Health care organizations should The MIHS policy on language and cultural competence provides for the
infuse CLAS goals, policies, and management periodic creation of a Language Needs Assessment for the population
accountability throughout the organization's served by the system. The Assessment incorporates information on the
planning and operations, number, proportion, and frequency of limited English proficient patients
may seek medical care from M1HS. Data is regularly collected on requests
for language services so that shifts in interpreting services can be detected
early. This on-going data collection and early detection is crucial to MIMS'
success in providing high-quality medical care to a culturally and
linguistically diverse patient population.
Standard 10: Health care organizations should Through the Initial Patient Registration Form, all patients at MHCC are -
conduct organizational assessments. asked to provide information on race, ethnicity and language needs. This
information is collected for inclusion in the patient medical record and the
various electronic systems used to report these data (e.g., CAREWare).
This information is collected from all MHCC patients.
Standard 11: Health care organizations should Through collaboration with the Arizona Department of Health Services,
collect and maintain demographic data. MIHS and MHCC are provided epidemiological data relating to people
living with HIV/AIDS in Maricopa County. When combined with the data
collection efforts mentioned for both Standard 9 and Standard 10, MHCC is
able to effectively plan for changes in cultural and language patterns in the
community of patients served.
Standard 12: Health care organizations should The MIHS Ryan White Part C and D Community Advisory Board (CAB) is a
conduct assessments of community health assets vital and active partner with Part C and D program staff to ensure that the
and needs. Part C and D program meets the needs of Part C and D patients. The CAB
is an enthusiastic group of HIV-infected and affected women, youth, and
their families and caregivers. The input solicited horn and provided by the
CAB is an integral part of designing and implementing CLAS-related
Page 12 of 14

Maricopa Integrated Health System
Ryan White Part A Services — Outpatient Ambulatory Medical Care Service
Solicitation 13126-REP
Standard. Addressed by MIHS
activities.
Standard 13: Health care organizations should MIHS and MHCC are committed to preventing cross-cultural conflicts by
partner witi the community. providing regular cultural diversity training to all staff. If conflicts or
complaints arise, all information is automatically available in both English
and Spanish. As with Standard 5, MIHS ensures that patients have all the
information they need concerning conflict and grievance resolution in a
Standard 14: Health care organizations should culturally MINS makes and every linguistically effort to meaningful keep the public manner. informed of progress made to
create conflict and grievance resolution meeting the CLAS standards. As just one example, on the MINS website
processes. (http:11www.mihs.org) there is a blurb and flyer available about the MIHS
Spanish Bilingual Assistant Classes. These classes are available to both
MIHS employees and non-employees in order to assist the wider
community to provide culturally and linguistically appropriate services.
Standard 15: Health care organizations should MU-IS continues to monitor our progress in sustaining CLAS as evidenced
communicate the organization's progress in by this table.
implementing and sustaining CLAS.
4. Ability to provide services by appropriately credential staff, including subcontractors.
District Medical Group. District Medical Group (DMG) is the exclusive nonprofit medical
provider for MIHS, and consists of over 400 providers representing all major medical and
surgical specialties / subspecialties including behavioral health. The mission of DMG is to
improve the health and well-being of individuals in Arizona through an integrated medical group
practice based on a balanced program of patient care, education, research and community
service. DMG provides comprehensive physician, allied professional and medical education
services for MIHS. DMG is grounded in serving the public by furthering the quality and safety
of health care services through medical education and research, addressing Arizona's needs
through training health care professionals, and improving access to care by means of innovation
in the delivery of medical services to all citizens regardless of circumstance.
All clinicians working at MHCC are licensed to practice medicine in Arizona. In addition, each
of them is an HIV Specialist as certified by the American Academy of HIV Medicine.
Behavioral health, dental and nursing staff also maintains licensure specific to their respective
fields. MHCC is recognized as a leader in the provision of high-quality integrated care designed
to meet the medical, behavioral and oral health needs of our patient population. This leadership
is evidenced, in part, by the fact that about one in every three PLWHA in Maricopa County
chooses to receive all or part of their healthcare at MHCC and MIHS.
The District Medical Group six strategic areas of focus are:
• Clinical Excellence and Community Health: Increase access to health services for the
community and elevate community health care standards.
• Partnership Development: Create effective, synergistic, and sustainable affiliations with
community programs, MIHS and University of Arizona.
• Education and Training: Expand academic programs while maintaining the highest
standards of academic performance and professional competence.
• Clinical Research Excellence: Create an institutional culture of exceptional scholarship
and strengthen the competitive quality and reputation of the clinical research enterprise.
Page 1.3 of 14

Maricopa Integrated Health System
Ryan White Part A Services —Outpatient Ambulatory Medical Care Service
Solicitation 13126-RFP
• Outstanding Workplace and Operational Excellence: Create a work environment that
fosters the highest standards of operational performance and fiscal discipline.
• Philanthropy and Public Value: Grow philanthropy and effectively promote the group's
unique public value.
Page 14 of 14

Attachment 2-D
CURRICULUM VITAE
JOHN M. POST, M.D.
1144 E. McDowell Road, Suite 300
PHOENIX, AZ 85006
(602) 344 6550
PERSONAL DATA
Birth Date September 21, 1945
Birthplace Hastings, Nebraska
Citizenship United States
Social Security Number 399-42-3867
Marital Status Married, Two Daughters
Home Address 901 East Van Buren St
41066
Phoenix, Arizona 85006
EDUCATION
High School Washington Park High School
Racine, Wisconsin
Graduated, 1963
College University of Wisconsin
Milwaukee, Wisconsin
Bachelor of Science, 1967
Medical School University of Wisconsin
Madison, Wisconsin
Doctor of Medicine, 1971
POSTDOCTORAL TRAINING
Internship (Rotating) Maricopa Medical Center
Phoenix, Arizona
1971-1972
Residency (Int. Med.) Maricopa Medical Center
Phoenix, Arizona
1974-1977
MILITARY SERVICES
General Medical Officer
United States Navy
1972-1974
LICENSURE
Arizona #8418

John M. Post, MD
Curriculum Vitae
-2-
CERTIFICATION
American Board of Internal Medicine 1977
American Academy of HIV Medicine. HIV specialist
Human Participants Protection Education for Research Teams (NIH) February 2005
Human Subjects Protection Certification (Rochester Program) December 2002
HOSPITAL APPOINTMENTS
Attending Physician
Department of Medicine
Maricopa Medical Center
Phoenix, Arizona
Phoenix Memorial Hospital
Phoenix, Arizona
Phoenix Rehabilitation Hospital
Phoenix, Arizona
CLINICAL EXPERIENCE
General Internist
Maricopa Medical Center
Phoenix, Arizona
1977 to present
ADMINISTRATIVE AND COMMITTEE RESPONSIBILITIES
Director, Outpatient Medical Services
1979-1990
Director, Acute Care Clinic
1988-1990
Medical Director, McDowell Healthcare Center
Center for HIV Infected Individuals
1990-present
Pharmacy and Therapeutics Committee
Member, 1981-1992
Chairman, 1985-1992
Credentials Committee, Member
1983-1988
Medical Council, Member at Large
1984-1985, 1990-1991

John M. Post, MD
Curriculum Vitae
-3-
Ambulatory Care Committee, Member
1986-1991
Ambulatory Care Q.A. Committee Chairman
1987-1992
Research Committee, Member
1988-1992
Member, AIDS Education and Training Center
Phoenix, Arizona, 1990-Present
Member, Arizona Department of Health Services
Adhoc Advisory Committee on Title ll Ryan White Care Act
1991-present
Member, Ryan White Title I Formulary Committee
1995-present
Arizona Health Care Cost Containment System (AHCCCS)
AIDS Advisory Committee
1996-2002
Member, Workgroup on HIV/Hepatitis C in the Arizona Correctional setting
Sub-Investigator, Phoenix Body Positive Clinical Trials
1995-Present
PROFESSIONAL MEMBERSHIPS
American College Of Physicians, Fellow
International Association Of Physicians In AIDS Care
International AIDS Society
Arizona Medical Association
American Academy of HIV Medicine
Infectious Disease Society of America
HIV Medicine Association of IDSA
TEACHING RESPONSIBILITIES
Hospital Ward Attending, HIV In-Patient Service
Attending McDowell Clinic
1990-present
HONORS AND AWARDS
Maricopa Medical Center Department Of Medicine Teaching Award, 1986
Malta Center Humanitarian Award, 1997

John M. Post, MD
Curriculum Vitae
-4-
Body Positive Unsung Hero Award 2002
PUBLICATIONS AND ABSTRACTS
XIV International AIDS Conference Barcelona, Spain, July, 2002
The Seroprevalence of Viral Hepatitis in HIV infected persons attending a clinic in the Southwestern
United States
J. Post M.D., C. Williams FNP, E. Post, D. Hobohm M.D.
XIII International AIDS Conference, Durban, South Africa, July 2000
An Open Label, Randomized, Trial Switching Nelfinavir From TID to BID: 96-Week Period.
J. Post, M.D., C. Williams FNP
Arizona American College Of Physicians Meeting, November 1998.
Immune Reconstruction Manifestation During Treatment Of Coccidiomycosis In A Patient. J.S. Carpenter,
M.D., (Associate), J.M. Post, M.D., Mayo Clinic Scottsdale Department Of Internal Medicine, Scottsdale,
Arizona. McDowell HealthCare Center, Phoenix, Arizona.
Infectious Disease Society Of America Meeting; Denver, Co, November 1998.
An Open Label Trial Changing Nelfinavir Dosing From TID to BID With Pharmacokinetic Analysis. A
Preliminary Report. J. Post, M.D., C. Williams FNP, M. Mulrow, J. Brake. McDowell HealthCare Center,
Phoenix, Arizona, Agouron Pharmaceuticals, Inc., La Jolla, C.A.
First International Conference On The Discovery And Clinical Development Of Antiretroviral Therapies, St.
Thomas, West Indies, December 13-17, 1998.
An Open Label, Randomized Trial Switching Netfinavir From TID to BID: Six Month Report.
J. Post, M.D., C. Williams FNP, M. Mulrow, J. Brake.
McDowell HealthCare Center, Phoenix, Arizona, Agouron Pharmaceuticals, Inc., La Jolla, CA.
RESEARCH
An Open-Label, Phase II Study of Amprenavir/Ritonavir or SaquInavir/Ritonavir In HV-Infected Subjects Following failure
with Kaletra (ABT-378/Ritonavir) as Their Second Protease Inhibitor Based HAART
An Open-Label, Phase II Study of Amprenavir/Ritonavir or Saquinavir/Ritonavir or Efavirenz in HIV-1 Infected subjects
Following Failure with Kaletra (ABT-378/Ritonavir) as Their First Protease Inhibitor Based HAART
A Randomized, Open-Label Study of 800mg Lopinavir/200mg Ritonavir OD in Combination with Tenofovir and
Emtricitabine vs. 400mg Lopinavir/100mg Ritonavir BID in Combination with Tenofovir and Emtricitabine in HIV-Infected
Antiretroviral Naive Subjects
A Randomized, Open Label Study Assessing Safety, Tolerability, Efficacy, and Metabolic Effects of a Simplified
Lopinavir/Ritonavir-Based Induction/Maintenance Therapy in Antiretroviral-Naive HIV-Infected Subjects
An Open-Label, Study of Pharmokinetics, Safety and Efficacy of Optimized Viracept Therapy as a Component of HAART
in Treatment Naive Subjects
Randomized, Open-Label, Comparative Safety and Efficacy Study of Tipranavir Boosted with Low-Dose Ritonavir
(TPV/RTV) Versus Genotypically-Defined Protease Inhibitor/Ritonavir (PI/RTV) In Multiple Antiretroviral Drug.
Experienced Patients (RESIST 1: Randomized Evaluation of Strategic Intervention in Multi-Drug Resistant Patients with
Tripanavir)
A Long-Term, Open-Label Rollover Trial Assessing the Safety and Tolerability of Combination Tipranivir and Ritonavir
Use in HIV-1 Infected Subjects
An Open-Label, Randomized, Parallel Group Pharrnacokinetics Trial of Tipranavir/Ritonavir (TPV/RTV), Alone or in
Combination with RN-Boosted Saquinavir (Soy), Amprenavir (APV) or Loprinavir (LPV), Plus an Optimized Background
Regimen, In Multiple Antiretrovirai (ARV) Experienced Patients

John M. Post, MD
Curriculum Vitae
-5-
An Open-Label, Non-Randomized, Treatment Protocol of TipranavIr Co-Administered with Low-Dose Ritonavir (TPV/r) in
Protease Inhibitor-Experienced Patients with HIV-I Infection (the Tipranavir Expanded Access Program)
A Phase II1B, Open-Label, Randomized, Multi-Center Study Evaluating the Effect on Serum Lipids Following a Switch to
Atazanavir (BMS-232632) in HIV Infected Individuals Evidencing Virologic Suppression on Their First P.I. Based
Antiretroviral Regimen
Atazanavir (BMS-232632) for HIV Infected Individuals Completing Atazanavir Clinical Trials: An Extended Access Study
An Exploratory Study of the Effect of the Atazanavir (AN)150L Mutation on Subsequent Treatment Response.
A Phase IIIB, Open-Label, Randomized, Multi-Center Study Comparing the Antiviral Efficacy, Safety, and Effect on
Serum Lipids of Atazanavir/Ritonavir Versus Lopinavir/Ritonavir, each in Combination with Tenofovir and either
Didanosine EC or Stavudine XR in HIV-1 Infected Subjects Receiving a NNRTI-Containing HAART Regimen who are
Experiencing their First Virologic Failure
Atazanavir (BMS-232632) for HIV Infected Individuals: An Early Access
A Phase Ili Randomized, Double-Blind, Multicenter Study of the Treatment of Antiretroviral-Nalve, HIV-1-Infected
Patients Comparing Tenofovir Disoproxil Fumarate Administered in Combination with Lamivudine and Efavirenz Versus
Stavudine, Lamivudine, and EfavirenzHAART Regimen to a Once Daily Regimen including Stavudine XR, Lamivudine,
and EfavirenzProgram
A Phase III, Randomized, Open-Label, Multi-Center Study of the Treatment of Antiretroviral Nerve, HIV-1-Infected
Subjects Comparing Tenofovir Disproxil Fumarate and Emitricitabine in Combination with Efavirenz Versus Combivir®
(Lamivudine/ZIdovudine) and Efavirenz
An Open-Label, Phase III Study to Assess the Long Term Safety Profile of GW433908 Containing Regimens in HIV-1
Infected Subjects
A Phase Ilb, 96 Week, Randomized, Open-Label, Multicenter, Parallel Group, Repeat Dose Study to Evaluate the Safety,
Tolerability, Pharmacokinetics and Antiviral Effect of Different Doses and Regimens of GW873140 in Combination with
Kaletra® (Lopinavir and RitonavIr) in HIV-1 Infected Antiretroviral Therapy Naïve Subjects
A Phase IIIB, Randomized, Open-Label, Multicenter Study of the Safety and Efficacy of GW433908 (700mg BID) Versus
Lopinavir/Ritonavir (400mg/100mg BID) when Administered in Combination with the Abacavirtamivudine
(600mg/300mg) Fixed-Dose Combination Tabled OD in Antiretroviral-Naive HIV-1 Infected Adults Over 48 Weeks
A Phase IV, Open Label, Multicenter Study of Treatment with Trizivir (Abacavir 300mg/Lamivudine 150mg/Zidovudine
300mg) Twice Daily and Tenofovir 300 mg Once-Daily for 48 Weeks in HIV-1 Infected Subjects Experiencing Early
Virologic Failure (Ziagen Intensification Protocol)
A Phase III, 48-Week, Open-Label, Randomized, Multi-Center Study of the Safety and Efficacy of the
Abacavir/Lamivudine Fixed-Dose Combination Tablet Administered QD Versus Abacavir +Lamivudine Administered BID
in Combination with a PI or NNRTI in Antiretroviral Experienced Patients
A Phase III Randomized, Open-Label, Multi-Center Study of the Safety and Efficacy of Efavirenz Versus Tenofovir When
Administered in Combination with the Abacavir/Lamivudine Fixed-Dose Combination Tablet as a Once-Daily Regimen in
Antlretroviral-Naive HIV-1 Infected Subjects
A Phase IV Multi-Center Study of the Efficacy and Safety of 48-Week Induction Treatment With Trizivir (Abacavir
300mg/Lamivudine 150mgaidovudine 300mg Combination Tablet BID) + Efavirem (600mg QD) Followed by 48-Week
Randomized, Open-Label, Maintenance Treatment With Trizivir I Efavirenz in HIV-1 Infected Antiretroviral Therapy Naïve
Subjects
A Pilot, Phase II, Open Label, Single Arm Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of
GW640385X when Administered with Ritonavir in Combination with Nucleoside Reverse Transcriptase Inhibitors for 48
Weeks in HIV-1 Infected Adults

John M. Post, MD
Curriculum Vitae
-6-
A Phase I, Multicenter, Double-Blind, Dose Ranging, Placebo-Controlled Study to Compare Antiviral Effect, Safety,
Tolerability and Pharmacokinetics of Four Oral Doses of GW695634G MonotheraPy Versus Placebo Over 10 Days in
ART-Naïve HIV-1 Infected Adults
A Probe Study of the Safety, Tolerability, and Immunogenicity of a 3-Dose Regimen of the MRKAd5 HIV-1 Gag Vaccine
in Healthy Adults
A Phase I, Dose-Ranging Study of Safety, Tolerability and Immunogenicity of the Merck
Trivalent Adenovirus Serotype 5 HIV-1 gag/pol/nef Vaccine (MRKAd5 HIV-1 gag/pot/net) in a Prime-Boost Regimen in
Healthy Adults
A Probe Study of the Safety, Tolerability and Immunogenicity of a 1-Dose Regimen of the MRKAd5 HIV-1 Gag Vaccine
Versus the ALVAC-HIV (vCP205) Vaccine in Healthy Adults Who Previously Received a 3-Dose Regimen of MRKAd5,
Ad5 or Placebo in Merck v520 Protocols 007 or 012
A Multi-Center, Double-Blind, Randomized, Placebo-Controlled Probe Study With and Additional Open-Label Control Arm
to Evaluate the Safety and Immunogenicity of a 3-Dose Regimen of the MRKAd5 HIV-1 gag Vaccine in Subjects With
Chronic Hepatitis C Virus Infection
A Randomized, Double-Blind, Controlled Dose Finding Study of NGX-4010 for the Treatment of Painful HIV-Associated
Distal Symmetrical Polyneuropathy
A Multicenter, Randomized, Double-Blind, Placebo Controlled Trial of A Novel CCR5 Antagonist, UK-427,857, In
Combination with Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of
Antiretroviral-Experienced HIV-1 Infected Subjects
A Multicenter, Randomized, Double-Blind, Placebo Controlled Trial of A Novel CCR5 Antagonist, UK-427,857, In
Combination with Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of
Anliretroviral-Experienced, Non-CCR5-Tropic HIV-1 Infected Subjects
A Phase III Open-Label Randomized, Active-Controlled Study Assessing the Efficacy and Safety of T-20/Ro29-9800
(HIV-1 Fusion Inhibitor) in Combination With an Optimized Background Regimen Alone, In Patients With Prior Experience
and/or Prior Documented Resistance to Each of the Three Approved Classes of Antiretrovirals (Nucleoside Reverse
Transcriptase Non-Nucleoside Reverse Transcriptase and Protease Inhibitors
An Open-Label Study Assessing Safety and Tolerability of Chronic Dosing with T-1249 in HIV-1 Positive Subjects Who
Have Failed Therapy with a T-20 Containing Regimen and Have Completed Study T1249-102
A Phase II, Randomized, Controlled, Partially Blinded, 48-Week Trial to Investigate Dose Response to TMC114/RTV in
Three Class Experienced, Multi PI-Experienced HIV-1 Infected Subjects
An Open-Label, 48-Week Trial of TMC114/RTV in HIV-1 Infected Subjects Who Failed Trial Treatment in the Control
group of sponsor selected trials with TMC114
A Randomized, Controlled, Partially Blinded Phase Ilb Dose-Finding Trial of TMC 125, in HIV-1 Infected Subject with
Documented Genotypic Evidence of Resistance to Currently Available NNRTIs and with at Least Three Primary PI
Mutations
An Open-Label of TMC125 in HIV-1 Infected Subjects who were Randomized to an Active Control Arm of any Sponsor-
Selected TMC125 Trial and either Virologically Failed of Completed the Entire Treatment Period
A Phase 2, Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Three-Arm Study of the Anti-CD4 Monoclonal
Antibody TNX-355 with Optimized Background therapy in Treatment-Experienced Subjects Infected with HIV-1
A Phase III Trial to Determine the Efficacy of Bivalent AIDSVAX B/B Vaccine in Adults at Risk of Sexually Transmitted
HIV-1 Infection in North America and Europe
An Open-Label Treatment Program to Provide Continued ACH-126,443 to Subjects of Previous Achlillon-
Sponsored Phase 2 Studies in HIV Infection
Double-Blind, Randomized, Dose Optimizing Trial of Three Doses of Tipranivir Boosted with Low Dose Ritonavir
(TPV/RTV) In Multiple Antlretroviral Drug-Experienced Subjects

John M. Post, MD
Curriculum Vitae
-7-
A Phase IV, Open Label, Multicenter Study of Treatment with Trizlvir (Abacavir 300mg/Lamivudine
150mg/Zidovudine 300mg) Twice Daily and Tenofovir 300 mg Once-Daily for 48 Weeks in HIV-1 Infected
Subjects Experiencing Early Virolagic Failure (Ziagen Intensification Protocol)
A Phase II, Randomized. Placebo-Controlled Study to Compare Antiviral Effect, Safety, Tolerability and
PharrnacokinetIcs of Four Oral Doses of S-1306 Versus Placebo Over 10 days in ART-Naive HIV-1 Infected
Adults
A Rollover Study of T-20 Administered in Combination with a Background Antiviral Regimen in 1-fIV-1 Positive
Adults Who Have Completed Clinical Thal T1249-101 or T1249-102
A Phase I/II Trial to Evaluate the Safety and Antiviral Activity of T-1249 in HIV-1 Infected Adults Who Have Failed
Treatment With T-20 and Background Antiretroviral Therapy and Demonstrate Reduced Susceptibility to T-20
A Randomized, Multi-center, Double-Blind, Phase III, Parallel Study Of Zidovudine (ZVD) Alone, Versus ZDV-
Zalcitabine (ddC), Versus ZDV-Ro 31-8959 (Proteinase Inhibitor, Saquinavir), Versus ZDV- ddC + Saquinavir In
Previously Untreated Or Minimally Pretreated HIV-Infected Patients With CD4 Counts From >50 To <350
Cells/mm3.
Phase III Ritonavir Long-Term Treatment Trial.
MSG 24 A Double-Blind, Randomized Trial, Comparing Oral Fluconazole To Placebo For The Prevention Of
Active Coccidioidomycoses And Other Systemic Fungal Infections In HIV-Infected Patients Living In The
Coccidioidal Endemic Areas.
Saquinavir Soft Gel: A Randomized, Multi-center, Parallel Arm, Comparative, Open-Label Study Of The Activity
And Safety Of Two Formulations Of Saquinavir, In Combination With Two Nucleoside Antqetroviral Drugs In
Treatment of Naive Patients.
A Continuation Protocol With Open Label Saquinavir, For HIV-Infected Patients Who Have Completed A Clinical
Trial With Saquinavir Treatment.
A Randomized, Placebo-Controlled, Double Blind, Parallel Group, Multi-center Study, With Open-Label
Extension, Of The Safety And Activity Of Saquinavir Soft Gelatin Capsule Formulation (Saquinavir-SGC) In
Combination With Other Antiretroviral Drugs.
ABT-378/R (ABT378/Ritonavir) Early Access Program
A Phase III Safety And Efficacy Trial Of ABT-538 Plus Current Therapy Versus Placebo Plus Current Therapy In
HIV-Infected Patients.
A Randomized, Double Blind, Phase III Study Of ABT-378/RitonavIr Plus Stavudine And Lamivudine Versus
Neffinavir Plus Stavudine And Lamivudine in Antiretroviral-Neve HIV-Infected Subjects,
A Randomized, Open-Label, Phase ill Study Of ABT-378/Ritonavir In Combination With Nevirapine And Two
Nucleoside Reverse Transcriptase Inhibitors (NRTIs) Versus Investigator Selected Protease Inhibitor(s) In
Combination With Nevirapine And Two NRTIs In Antiretroviral-Experienced HIV-Infected Subjects.
A Randomized, Double-blind, Adjuvant-controlled, Multicenter Study to Compare the Virologlc and Immunologic
Effect of Highly Active Antiretroviral Therapy (HAART) Plus REMUNETm Versus HAART Plus Incomplete
Freund's Adjuvant (IFA) in Antiretroviral-naive Patients Infected with Human Immunodeficiency Virus type 1 (HIV-
1)
A Phase II, single-blind, randomized, Placebo-controlled Study of Capravirine (AG1549) in Combination with
VIRACEPTTha and Two Nucleoside Reverse Transcriptase Inhibitors in HIV-infected subjects who Failed an Initial
Nonnucleoside reverse Transcriptase Inhibitor Containing Regimen
A Phase III, Randomized, Double Blind, Placebo-Controlled Study Of Viracept Administered In Combination With
Zidovudine (AZT) + Lamivudine (3TC) Versus Zidovudine (AZT) + Lamivudine (3TC) Alone In HIV Positive
Patients With Less Than One Month Or No Prior Antiretroviral Treatment.

John M. Post, MD
Curriculum Vitae
-8-
(d4t) Versus Stavudine (d4t A Phase III, Randomized, Double Blind, Placebo-Controlled Study Of Viracept In
Combination With Stavudine) Alone In HIV Positive Patients.
A Multi-Center, Double Blind, Phase ill, Adjuvant-Controlled Study Of The Effect Of 10 Units Of HIV-Immunegen
Compared To IFA Alone Every 12 Weeks On AIDS-Free Survival in Subjects With HIV Infection And C04 T-
Lymphocytes Between 300 And 549 Cells, Regardless Of Concomitant HIV Therapies.
A Phase II, Randomized, Double-Blind Placebo-Controlled Study Of Combination Drug Antiviral Therapy To
Include A Reverse Transcriptase Inhibitor And A Protease Inhibitor Plus HIV-IT (V) Or Placebo In HIV Patients
With CD4 Counts > 100, And HIV RNA > 1K But < 10K.
A Randomized, Phase II, Stratified, Open-Label, Multi-Center, Study Of The Safety And Efficacy Of Adefovir
Dipivoxil And Indinavir In Combination With Zidovudine, Lamivudine Or Stavudine For The Treatment Of Therapy
Naïve HIV-Infected Patients With CD4 Cell Counts > 100/mm3 And HIV-RNA Copy Numbers > 5,000
Equivalents/mL.
A Phase II, Stratified, Randomized, Open-Label, Multi-Center Study Of The Safety And Efficacy Of AdefovIr
Dipivoxil At Two Dose Levels In Triple Combination Therapies With Protease Inhibitors For The Treatment Of
HIV-Infected Patients With CD4 Cell Counts > 100/mm3 And HIV-RNA Copy Numbers > 5,000 Equivalents/mL
And Prior RTI Therapy But No Prior PI Therapy.
PREVEON (adefovir dipivoxil, GS840) Expanded Access Program
A Randomized, Open-Label, Expanded Access Program To Evaluate The Safety Of Preveon (Adefovir Dipivoxii)
At Two Dose Levels When Used in Combination With Other Antiretroviral Agents For The Treatment Of Patients
With HIV Infection Who Have Limited Treatment Options.
Expanded Access Program for Tenofovir Disoproxil Fumarate (Tenofovir DF) in the Treatment of HIV-1 Infected
Patients Who Have Limited Treatment Options
A Compassionate Use Protocol For Thalidomide In The Treatment Of Recurrent Aphthous Stomatitis (RAS) In
HIV-Infected Patients.
A Double Blind, Dose Comparison Trial Of Thalidomide For The Treatment Of Recurrent Refractory Aphthous
Stomatitis (RAS)
An Open-Label Study Of The Effect Of Thalidomide On Body Composition In Adults With HIV Associated
Wasting
A Randomized Open-Label Study of the Antiviral Efficacy and Safety at Atazanavir Versus Lopinavir/Ritonavir
(LPVIRTV), Each in Combination with Two Nucleosides in Subjects Who Have Experienced Virologic Failure with
Prior Protease Inhibitor-Containing HAART Regimens.
A Phase III Study Comparing the Antiviral Efficacy and Safety of BMS-232632 with Efavirenz; Each In
Combination with Fixed Dose Zidovudine-Lamivudine
A Randomized Study Of The Long-Term Suppression Of Plasma HIV RNA Levels By Triple Combination
Regiments In Treatment Naïve Subjects.
Evaluation Of HIV RNA Suppression Produced By A Triple Combination Regimen Containing An Enteric
Administered Once Daily Compared To A Reference Combination Regimen.
An Open Label Study Of The Safety And Tolerability Of Valgancidovir, An Oral Prodrug Of Gancidovir, For The
Treatment Of CMV Retinitis In Subjects With AIDS.
A Randomized, Controlled Comparison Of The Safety And Efficacy Of Ro 107-9070, (Valganciclovir) Versus IV
Ganciciovir As Induction Therapy For The Treatment Of Newly Diagnosed CMV Retinitis.
A phase III open-label, randomized, active-controlled study assessing the efficacy and safety of T-20/Ro 29-9800
(HIV-1 fusion inhibitor) in combination with an optimized background regimen, versus optimized background
regimen alone, in patients with prior experience and/or prior documented resistance to each of the three classes
of approved antiretrovirals (nucleoside reverse transcriptase, non-nucleoside reverse transcriplase and protease
inhibitors).

John M. Post, MD
Curriculum Vitae
-9-
A phase ill open-label, randomized, active-controlled study assessing the efficacy and safety of T-20/Ro 29-9800
(HIV-1 fusion inhibitor) in combination with an optimized background regimen, versus optimized background
regimen alone, in patients with prior experience and/or prior documented resistance to each of the three classes
of approved antiretrovirals (nucleoside reverse transc,nptase, non-nucleoside reverse transcriptase and protease
inhibitors).
A Phase II, Randomized, Double Blind Placebo-Controlled Study Of The Safety And Antiviral Activity Of The
Addition Of PMPA Prodrug To Combination AntiretrovIral Regimens In Treatment-Experienced HIV-Infected
Patients.
A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Of The Safety And Efficacy Of
Tenofovir Disoproxil Fumarate in Combination With Other Antiretroviral Agents For The Treatment Of HIV-1
Infected Patients.
An Open-Label, Multi-Center, Compassionate Access Study of the Safety of Tenofovir Disoproxil Fumarate
Administered in Combination with Other Anti-retroviral Agents for the Treatment of 1-11V-1 Infected Patients
A Phase III, Open-label, Multicenter Study of the Safety of Tenofovir Disoproxil Fumarate Administered in
Combination with Other Antiretroviral Agents for the Treatment of HIV-1 Infected Patients
A Phase III, Multi-Center, Randomized, Open-Label Study To Compare Antiretroviral Activity And Tolerability Of
Three Different Combination Regimens (DMP 266 + Indlnavir, DMP 266 + Zidovudine + Lamivudine, Indinavir +
Zidovudine + Lamivudine) In HIV-infected Patients.
A Randomized, Open-Label, Expanded Access, Program To Evaluate The Safety Of Sustiva (Efavirenz) When
Used In Combination With Other Antiretroviral Agents For The Treatment Of Patients With HIV infection Who
Have Limited Treatment Options.
A Phase III, Randomized, Multi-Center, Parallel-Group, Open-label, Three-Arm Study to Compare the Efficacy
and Safety of Two Dosing Regimens of GW4339081 Ritonavir (700mg/100mg Twice Daily or 1400mg/200mg
Once Daily) Versus Lopinavir / Ritonavir (400mg/10OrngTwice Daily) for 48 weeks in Protease Inhibitor
Experienced HIV-Infected Adults Experiencing Virological Failure
A Phase 11/11I 48 Week, Randomized, Double-Blind, Controlled, Multicenter Study to Evaluate the Efficacy and
Safety Of Lamivudine 300mg Once Daily vs Lamivudine 150mg BID in Combination with Zidovudine 300mg BID
and Efavirenz 600mg Once Daily In Antiretroviral-NaIve Adults with HIV-1 Infection
A phase III, 1:1 randomized, double-blind, controlled, multicenter trial comparing the efficacy and safety of
abacavir versus zidovudine when combined with lamivudine and efavirenz for treatment of HIV-1 infection in
antiretroviral therapy naïve adults'
A Retrospective, Case-Control Study to Investigate Genetic Polymorphisms in HIV Infected Subjects Who
Developed Hypersensitivity Following Treatment With Abacavir
A Phase II, Open-Label, Randomized Study to Compare the Efficacy and Safety of EPIVIR/Z1AGEN/ZERIT
(3TC/AF3C/d4T) Versus EPIVIR/ZIAGENISUSTIVA (3TC/ABC/EFV) Versus
EPIVIR/Z1AGEN/GW433908/NORVIR (3TC/ABC/908/RTV) for 96 Weeks in the Treatment of HIV-1 Infected
Subjects Who are Antiretroviral Therapy Naive.'
A Phase 11B, Randomized, Multicenter Study Of The Efficacy And Safety Of Combivir® Plus Ziagen® 300 Mg PO
BID Versus Abacavir/Lamivudine/Zidovudine Table (300/150/300 Mg Abacavir/Lamivudine/Zidovudine) PO BID,
When Administered For 24 Weeks In Subjects With HIV-1 Infection
An Open-Label Protocol For Adult Patients With HIV-Infection. Protocol Part A and B.
An Open-Label Compassionate Use of Nitazoxanide for the Treatment of Cryptosporidiosis in AIDS Patients
A Randomized, Double Blind Study Of MKC-442 Combined With Stavudine, Didanosine, And Hydroxyurea In
HIV-Infected Patients Who Are Protease Inhibitor Experienced And Non-Nucleoside Reverse Transcriptase-
Inhibitor Naïve.
Procrit Once A Week Vs. Placebo In The Treatment Of Anemia In HIV-Infected Patients.

John M. Post, MI)
Curriculum Vitae
-10-
A Treatment Ind. Protocol for the Use of Videx (ddi)—Bristol-Myers Squibb
An Open-Label Study Regimen of Videx (ddl)—Bristol-Myers Squibb
A Randomized Blinded Evaluation of Two Doses of Stavudine (d4T)—Bristol-Myers Squibb
An Open-Label Safety Study of Didoxycytidine (ddC)—Roche Laboratories
A Randomized Controlled Multi-Center Trial of Fllgrastim (G-CSF) for the Prevention of Grade 4 Neutropenia in
Patients with HIV Infection—Am Gen
A Three-Arm Comparative Trial for the Treatment of MAC Bacteremia in AIDS: a Clarithromycin/Ethambutol
Regimen Containing Rifabutin, 900 mg; Rifabutin, 600 mg: or Placebo Adria Laboratories
A Double-Blinded Randomized Placebo-Controlled Study of Fluconazole in the Prevention of Active
Coccidioidomycoses and Other Systemic Fungal Infections in HIV Infected Patients Living In the Coc.cidioidal
Area--Pfizer/NIAID Mycosis Study Group
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Viracept Administered in Combination with
Zidovudine (AZT) + Lamivudine (3T0) versus AZT + 3TC Alone in HIV Positive Patients with Less Than One
Month or No Prior Antiretroviral Treatment.
A Continuation Protocol with Open Label Saquinavir for HIV Infected Patients who have Completed a Clinical
Trial with Saquinavir Treatment.
A Phase III Randomized, Double-Blind, Placebo-Controlled Study of Vlracept In Combination with Stavudine
(d4T) versus Stavudine (d4T) Alone in HIV Positive Patients.
A Randomized, Multicenter, Double-Blind, Phase III, Parallel Study of Zidovudine (ZDV) Alone, versus ZDV +
Zalcitabine (ddC), versus ZDV + Ro 31-8959 (Protease Inhibitor, Saquinavir), versus ZDV + ddC + Saquinavir in
Previously Untreated or Minimally Pretreated HIV Infected Patients with CD4 Counts from 50 to s 350
cells/me
A Randomized Controlled Trial Comparing Standard Hepatitis B Vaccination to an Enhanced Vaccination
Protocol in HIV Seropositive Patients.
A Phase IV Randomized Study of the Use of Fluconazole as Chronic Suppressive Therapy versus Episodic
Therapy in HIV Positive Subjects with Recurrent or Oropharyngeal Candidiasis
A Multicenter, Randomized, Controlled, Open-Label Study to Determine the Efficacy of Filgrastim (r-metHuG-
CSF) in the Reduction of Bacterial Infections in AIDS Patients.
A Double-Blind, Placebo-Controlled Study Comparing the Combination of 15% SP-303 Gel with Acyclovir Versus
Acyclovir Alone for the Treatment of Recurrent Herpes Simplex Virus (HSV) Infections in Subjects with AIDS.
An Open Compassionate Use Study of Iverrnectin in the Treatment of Patients with Scabies.
A Randomized, Open-Label, Multicenter Study of the Safety and Efficacy of Adefovir Dipivoxil and Indinavir in
Combination with Zidovudine, Lamivudine or Stavudine for the Treatment of Therapy Naive HIV Infected Patients
with CD4 Cell Counts 100 Cells /mm3 and HIV-RNA Copy Numbers 5,000 Equivalents/mL.
A Randomized, Open-Label. Multi-Center Study of the Safety and Efficacy of Adefovir Dipivoxll Two Dose Levels
in Triple Combination Therapies with Protease Inhibitors and Nucleoside Reverse Transcriptase Inhibitors for the
Treatment of HIV Infected Patients with CD4 Cell Counts 100/mm 3 and HIV-RNA Copy Numbers 5,000
Equivalents/mL and Prior RTI Therapy But No Prior PI Therapy.
A 1592U89 Open-Label Protocol for Adult Patients with HIV-1 Infection.
A Phase III, Multicenter, Randomized, Open-Label Study to Compare Antiretroviral Activity and Tolerability of
Three Different Combination Regimens (DMP 266 + lndinavir, DMP 266+ Zidovudine + Lamivudine, Indinavir +
Zidovudine + Lamivudine) In HIV Infected Patients.
AG-632 An Open Label, Randomized Trial Switching Nelfinavir From TID to BID.

John M. Post, MD
Curriculum Vitae
-11-
A Randomized Controlled Trial Comparing Standard Hepatitis B Vaccination To An Enhanced Vaccination
Protocol In HIV Seropositive Patients.
A Randomized, Multi-center, Double-Blind, Phase III, Parallel Study Of Zidovudine (ZVD) Alone, Versus ZDV-
Zalcitabine (ddC), Versus ZDV-Ro 31-8959 (Proteinase Inhibitor, Saquinavir), Versus ZDV-ddC + Saquinavir In
Previously Untreated Or Minimally Pretreated HIV-Infected Patients With CD4 Counts From >50 To <350
Cells/mm3.
GS-95-120: Vistide (Cidofovir Intravenous) treatment IND Protocol for Relapsing Cytomegalovirus Retinitis in
Patients with AIDS
98-40: A Double-Blind, Randomized, Placebo-Controlled, Multi-Center Study to Assess the Efficacy and Safety of
Orally Administered SP-303 for the treatment of Diarrhea in Acquired Immunodeficiency Syndrome (AIDS)
Patients
93-78: Oral vs. Intravenous Gancyclovir for the Treatment of CMV Rethills in People with HIV Infections
94-10: A Comparative Trial of Valacyclovir and Acyclovir for Suppression of Anogenital Herpes
62979/030: The Efficacy and Tolerability of Albendazole in the Symptomatic Improvement of Diarrhea Caused by
Microsporidia in HIV Infected Patients. An Open-Label Compassionate Use Study
92 IALM 013: A Phase Ill Controlled. Double-blind, Randomized, Multinational Study for the Preventative therapy
of Latent Tuberculosis in HIV Positive Individuals: lsoniazid (300mg/d x 12 months) vs. Rifabutin (300mg/d x 3
months)
AG 632: An Open-Label, Randomized Trial Switching Netfinavir From TID to BID,
96-65: The Seroprevalence of Viral Hepatitis in HIV infected Patients Attending A Community Primary Care Cilinic
200-24 HIV Research Network
John M. Post, M.D. Date

4.11..
9/15/]
MD PROFILE PAGE ;
Arizona Ifledltai Board
azmdlov
Printed Oil tiffilfet3 @ 01:17
Gervaral Information •
Jet* M. Post IAD License Number: 8418
McDowell 1101 N Central Healthcans Av -Cenbar License Status: Active
Ste 204 Licensed Date: 0910511974
.Pheenix AZ now Due Licerrie to Renew Renewed: By: 0812112015 09/15/2013
Phone: (002) 344-6550 If not Renewed, License •xpices: 01r21/2016
Education and Training
Medical School: UMW OF %ARMED SCI-I
MADISON, Wisconsin
c3roaduation Date: 06/141971
Internship: 07101/1971 - maw 972
MARICOPA MEDICAL CENTER
PHOENIX. AZ
Residency: 07/01/1974 (Internal Medicine)
fiitARICOPA MEDICAL CENTER
PHOENIX , AZ
Area of Interest Internal Medicine
Area of Interest HIV/AIDS
tp://wwicearnd.govigisuiterilebicilentsJaztiorn/PublIc/Prolile.aspxlentID..1613069&11c1D=276843411cTypv•i&Print=1
Page

Ann Khalsa, M.D.
BIO
Ann Khalsa, MD, has worked in the field of HIV medicine since 1986, From 2006-2010
she was the Medical Director at the Centro de Salud Familiar La Fe HIV/AIDS C.A.R.E.
Center in El Paso Texas which cares for over 1000 patients living on the US-Mexico
Border. She held a clinical appointment as an Assistant Professor of Family Medicine at
the Texas Tech University Health Science Center and also served as the Clinical Director
at the Texas-Oklahoma AIDS Education and Training Center Local Performance Site in
El Paso Texas. For the fifteen years prior to that she worked at the University of Southern
California in Los Angeles as an Associate Professor of Clinical Family Medicine at the
USC Keck School of Medicine where she also she served as the Director of Clinical
AIDS Training for the Pacific AIDS Education and Training Center at USC, and
chairperson for part of the medical school curriculum. During that time she cared for over
1000 patients at the LA County Rand Schrader and Maternal-Child AIDS clinics, and
trained over 1000 local and international physicians in the care of HIV patients. She
started off in the HIV field by doing four years of AIDS policy work through the Public
Health Commission of the American Academy of Family Practice during medical school
and residency.
Dr. Khalsa is certified as an HIV Specialist through the American Academy of HIV
Medicine, has served on the national Board of Directors, the Academy's Core Curriculum
Committee to develop its "Fundamentals of HIV Medicine" self-study guide, and has
authored chapters on Health Maintenance and antiretroviral therapy for treatment-
experienced patients. She served on the Texas Steering Committee for the HRSA
HIV/AIDS Bureau-National Quality Center Cross-Part Quality Management
Collaborative, as well as on the Quality Management Committee of the Ryan White Title
II Administrative Agency for the West Texas Health Service Delivery Area. She lectures
on HIV-related topics to providers and patients alike, in both English and Spanish
throughout the country and internationally.
She is board certified by the American Board of Family Practice, was awarded the US-
Mexico Border HIV Hero Award in 2008, is a recipient of the Mead Johnson Award for
Graduate Education in Family Practice, and a member of the Alpha Omega Alpha
Medical Honor Society. Dr. Khalsa obtained her undergraduate degree from Pitzer
College in Claremont California with honors in Psychobiology, and her medical degree
from USC. She did her residency training at San Bernardino County Medical Center in
California, holds master's degrees in Biochemistry and Medical Education, and
completed a Fellowship in Leadership Development at USC.

Profile
Page 1 of
MD PROFILE PAGE
Arizona Medical Board
azrrid.gov
Printed on 10/28/13 @ 02:56
General Information
Ann Marie Khalsa MD License Number: 43010
tvtaricopa Integrated Health System License Status: Active
McDowell Clinic Licensed Date: 05/19/2010
1144 E McDowell Rd #300 License Renewed: 09/30/2012
Phoenix AZ 85006 Due to Renew By: 10/21/2014
Phone: (602) 344-6550 • If not Renewed, License Expires: 0212112015
Education and Training
Medical School: KECK SCH OF MED OF THE USC
LOS ANGELES, CA
Graduation Date: 05/08/1987
Residency: 07/01/1987 - 06/30/1990 (Family Medicine)
ARROWHEAD REGIONAL MEDICAL CENTER
COLTON, CA
Area of Interest Family Medicine
The Board does not verify current specialties. For more information please see the American Board of
Medical Specialties wetasite at http://www.abms.org to determine if the physician has earned a
specialty certification from this private agency.
Board Actions
None
http://www.azmd.gov/gIsuiteweb/clients/azbom/Public/Profile.aspx?entlID=171484784licl.. . 10/28/2013

1028113 Crane Verfication DeWitt
CAROL HENSLEY WILLIAMS
AP0225
ADV PRACTITIONER
Original License Date: 12/11/1985
Due For Renewal: 4/1/2017
Lawful Presence: Verified
License Status: 12/11/1985 - ACTIVE: GOOD STANDING,
612/2013 - AP ISSUED PRIOR TO NAIL CERT
REQUIREMENT,
711/2002 - VALID IN ARIZONA ONLY
Prescribing Privileges: YES
Dispensing Privileges: YES
AP Specialty Type: FAMILY NURSE PRACTITIONER
Fingerprints: NO; Not required if originally licensed in Arizona
prior to 1/111999
The Arizona State Board of Nursing's online verification system is a free service provided to licensees, certificab
holders, employers and the public for primary source verification. In addition to verifying the person is licensed c
certified through the website, users are encouraged to ask to view the current license/certificate, request a
picture identification such as a drii.er's license or passport or Social Security card to verify the person's identity.
(Note: Accepting a photo copy of the license may not be a reliable verification that the person is licensed.)
www.aangcniOnlineVerificalionDetails_aspeAd=369:18certi&10099311printotrue

Carol Elise Williams, FNP
McDowell Healthcare Clinic
1101 N. Central Avenue
Phoenix, Arizona 85004
EXPERIENCE
1991 Present NURSE PRAC 1.11 IONER / HIV
McDowell Healthcare Center - Director of Women's Clinic
Dept of Medicine - DMG
1101 North Central Avenue
Phoenix, Arizona 85004
2001 - 2009 NURSE PRACTITIONER / WV
Spectrum Medical Group
52 East Monterey Way
Phoenix, Arizona 85012
1995 - 2001 SUB-INVESTIGATOR, CLINICAL TRIALS / BTV
Southwest Center for HIV / AIDS
1144 East McDowell Road, Suite 200
Phoenix, Arizona 85006
2002 - 2009 SUB-INVESTIGATOR, CLINICAL TRIALS / IIIV
Spectrum Medical Group
52 East Monterey Way
Phoenix, Arizona 85006
1980 - 2001 CHIEF NURSE, Lt.Col. (Rd.)
21 years (last duty- Chief Nurse)
United States Air Force Reserves
944th Medical Squadron
Luke AFB, Arizona
1980- 1991 NURSE PRACTITIONER
Maricopa County Ambulatory Care - 7th Ave PCC
1407 South 9th Avenue 3 years
Also MIHS Walk-in Clinic, Dept of Medicine 3 years,
MIHS Emergency Department 5 years
Phoenix, Arizona
1976- 1980 REGISTERED NURSE
Maricopa Medical Center
Medical Intensive Care Unit
TRAINING:
\‘gb \`'Ov-)\

August, 1985 B.S.N. Grand Canyon University
September, 1980 Maricopa County Hospital / University of Arizona
Emergency / Primary Care Nurse Practitioner Program
Certificate
December, 1976 A.D.N.
Scottsdale Community College
CREDENTIALS:
FNP — DEA Current, Arizona
National Board Certification
American Nurses Association
Certificate 026251-22 - Current
RN License Arizona 036708 - Current
.American Academy. of HIV Medicine
Certified — Current
PROFESSIONAL ACTIVITIES:
American Academy of HIV Medicine
RESPONSIBILITIES:
Director, Women's Clinic -- McDowell Healthcare Clinic
Preceptor, Arizona State University, Grand Canyon University,
Stills University

SERIAL 13126-REP
Attachment 2-E
RESPONDENT'S REFERENCES
RESPONDENT SUBMITTING PROPOSAL: Maricona Integrated Health System
1. COMPANY NAME: Phoenix Children's Hospital
ADDRESS: 1919 E. Thomas Road, Phoenix. AZ 85016
CONTACT PERSON: Jan Piatt. M.D.
TELEPHONE: 602-202-1260 E-MAIL ADDRESS: ipiatt@phoenixchildrens.org
2. COMPANY NAME: District Medical Group
ADDRESS: 2929 E. Thomas Rd., Phoenix, AZ 85016
CONTACT PERSON: Kote Chundu. M.D., President and CEO
TELEPHONE: 602-470-5000 E-MAIL ADDRESS: kote chunduadmgaz.org
3. COMPANY NAME: Maricopa County Department of Public Health
ADDRESS: 1645 E. Roosevelt St., Phoenix, AZ 85006
CONTACT PERSON: Tom Mickey. STD Program Manager
TELEPHONE: 602-506-6364 E-MAIL ADDRESS: tommickey@mail.maricopa.gov
4. COMPANY NAME:
ADDRESS:
CONTACT PERSON:
TELEPHONE: E-MAIL ADDRESS:
5. COMPANY NAME:
ADDRESS:
CONTACT PERSON:
TELEPHONE: E-MAIL ADDRESS:

Attachment 2-F
DEPARTMENT OF HEALTH AND HUMAN SERVICES • Program Support Center
Financial Management Service
DivIslon of Cost Allocation
DCA Western Field Office
90 7th Street, Suite 4•800
San Francisco, CA 04103
PHONE (415)437-7820
JUL 29 2013 FAX: (415) 437-7823
dcasf@pschhs.gov
Kathleen Benaquista
Controller
Maricopa integrated Health System
2819 East Pierce St., 1st Fl.
Phoenix, AZ 85008
Dear Ms. Benaquiste:
A copy of an indirect cost Negotration Agreement is attached, This Agreement reflects
an understanding reached between your organization and a member of my staff
concerning the rate(s) that may be used to support your claim for Indirect costs on
grants and contracts with th'e Federal Government. Please have the Agreement signed
by a duly authorized representative of your Organization and return It to me BY EMAIL
OR FAX retaining the copy for your files. We will reproduce and distribute the
Agreement to the appropriate awarding organizations of the Federal Government for
their use,
An indirect cost proposal together with required supporting information must be
submitted to this office for each fiscal year In which your organization claims indirect
costs under grants and contracts awarded by the Federal Government. Thus, your next
proposal based on your fiscal year ending 06/30/13 is due In our office by 12/31/13.
Sincere!
Arif prim, Director
Division of Cost Allocation
Attachment
PLEASE SIGN AND RETURN THE NEGOTIATION AGREEMENT BY EMAIL OR FAX

HOSPITALS RATE AGREEMENT
EIN: DATE:07/22/2013 ,
ORGANIZATION: FILING REF.: The preceding
Maricopa Integrated Health System agreement was dated
2619 East Pierce St., let F1. 06/23/2010
Phoenix, AZ 85008
The rates approved in this agreement are for use on grants, contracts and other
agreements with the Federal government, subject to the conditions in Section III.
SECTION It INDIRECT COST RATES
RATE TYPES: FIXED FINAL PROV, (PROVISIONAL) PRED. (PREDETERMINED)
EFFECTIVE PERIOD
IX211 FROM FATE (%) XIOCATICHNI AE1ticABL1 TO
PRED, 07/01/2012 06/30/2014 25.00 All Other Sponsored
Activities
PRED. 07/ 0 1/2012 06/30/2014 63 .00 All Research
PROV. 07/01/2014 06/30/2015 25.00 All Other Sponsored
Activities
PROV. 07/01/2014 06/30/2015 63 .00 All Research
Total direct costs excluding capital expenditures (buildings, individual items
of equipment; alterations and renovations); subawards; hospitalization and
other fees associated with patient care whether the services are obtained from
an owned, related or third party hospital or other medical facility;
rental/maintenance of off-site activities; student tuition remission and
student support costa (e.g., student aid, stipends, dependency allowances,
scholarships, fellowships).
Page 1 of 3 H33022

ORGANIZATION: Maricopa Integrated Health System
AGREEMENT DATE: 7/22/2013
SECTION II: SPECIAL REMARKS
ILEATEUREL-U—EILIZIOE-15211ELIM_
The fringe benefits are specifically identified to each employee and are
charged individually as direct costs. The directly claimed fringe benefits are
listed below.
TREATMENT OF FAIL ABSENCES
Vacation, holiday, sick leave pay and other paid absences are included in
salaries and wages and are claimed on grants, contracts and other agreements
as part of the normal cost for salaries and wages. Separate claims are not
made for the cost of these paid absences.
DEFINITION OF EQUIPMENT
Equipment is defined as tangible nonexpendable personal property having a
useful life of more than one year and an acquisition cost of $5,000 or more
per unit.
The following fringe benefits are treated as direct costs:
FICA, HEALTH/LIFE INSURANCE, AND RETIREMENT.
Page 2 of 3

ORGANIZATIONt Maricopa Integrated Health Systeth
AOREEMENT DATE 7/22/2013
SVCTION I/I1 GENERAL
• . 14/132621171"
The rates in this egreememb Iwo suhjeot to wry statutory or adninietrative itatetiOne roll only to d given great'
contract or other egreemeat ocly to the extent that Arida are available. hceoptanee of the rots. is auhjeot to the
fo1lo4ing nonditionap (11 Only cootio itourred by the organieetion mere included in ite indiVaet °Oat pool es finally
atoeptede Been al:Alta...1'13 legal chligatiene of tha organisation and axe allOWShle nadir ths governing cost principles)
(2) The Naha Mita that bin e been treated en indirect Conte are tot claimed lee direct cants] {a) aiolux types of poets
have born accorded conaistant accounting treatmeet; and (a) The information provided by the organisation which wee aged to
establish the velem is not leter found to he meterially inaomplote or inaccurate by the Federal devernieot. Xis such
'situation', Mho rate(0) Weald he enhjoot to renegotiation at the clic:motion of the Wederal government.
S. ACIMMEMS1123531111.
?hie agroonent is belied an the accounting Oates pUrported by ths organisation to he in *Mot during the agreement
period. Changed to the method of aciddranting for aorta whioh offset tho mount of ralohusencent resulting from the use of
this Agreement require prior approval el the authorised representative of eh. megnimeet agenoy. Ouch changes include, hot
are not limited to changor in tho oharging of a yamtionLar typu of coot boo indirect to direet, run= t.0 Obtain
opsmovsl may mvoult in neat disallowenoes.
01 frIGIILELIZILL
If a fixed xote is in this agxaasont, it le hated on en estimate of the meta far the period covered JOy mu rata. When the
easel mete far We period are determined, on adjustment edll he nade to a rate of a future yearfe) to oospeoeste for
the difference between the meta used to establish the fixed role and actual omits,
P. IZELZI-CMPLERE
The ratee in thil Itgretnant Wins appl'aped in ocoordanna with the coat principien yoenaloeted by mil; popartAwit of sualtb
and Henan Perviese. and °haul& be molted to the grants, °entreats and other egreeseate covered by these regaations
subject to any limitations in above. The hospital airy provide copiee of th6 horeloant to atter rodomol Agenoit0 to give
then early notification of the Agreement.
B. =Hai
If any vedammil cloormnot, grant or other agreement is reisborming indireot caste by a some other than the epproved rats Li)
in thio ngreaseat, the orgeoleation should (1) credit amen costs to ths affdobwilmogress. Mad (2) apply rho osismovod
rnEn rs) to the appropriete heat to id4ntify the proper amount of indirect coats alloombla CO them( Programa.
4Be IMITIVCRIOnt OW WHO, or TAX rwOOloa. °ova:root,
Maricopn Integrated Medlar aymtem
At-if iGirbn
DunUA
digeotor, division om cost Minnation
7/12/2011
(Min 3022
Mae MiroaruarrroVol Balm Pung
reamboomi (415) 437 ,-7620
Page 3 of 3

MD MC
MD Behavioral Licensed Professional Counselor Lankton, 2013
Chair Psychiatry Olson, of Health Shpitelniic, Julie 12,
Carol Director Zhanna
November
Providers ANA FNP
MPH Medicine MD Director MD te Director Arey, Williams, Updated
President Officer MD, Chair Weisincier, Khaisa, L=L Medical J n Medical Brian Carol
Vice Medical Fromm, Jr., Internal David Medical Ann ,
Senbr Chief E D , Goo-dination Stanton
Robert Manager Part Advocate Brown Lindedri
Program White Lormey Family Lorraine CooriEnater NAirstre Dental Candes
Administration HIV Ryan Beni J
Director Trinson I
Grants Oh Manager Part C Spedatist Guerrero Navigator Valdez Patient Fahnbulleh Vyamungu
Program White Moore ate Entry Carmen Patient Hector Cultural Navigators Massa Venant
Eric
District Ryan
2-G Care
Health Officer Specialist Garay Jaime Serrato Ledastna Lopez
Directors President Executive Purves Office Cede Effgibility Maria Schedulers/Clerks Susanne Alice Etizabeth Martha Vacant
Attachment Special of Stephen Supervisor
Board Front Veronica
County Chief
Maricopa Assistants Bell Smiley
rector Nursing 1.1 RN Lab Adriana Elizabeth
P I tt.,‘, Manager Scaggs,
°cave Ambulatory ;1.0 Chic Greg Assistants Ortiz Prod('
IArl Vital Ann Vacant
Medical Roxanne Jose Mary
Services RN RN RN
President Officer Vanaskie Physician JACC4 Registered Nurses Miler, Roland, Dunn,
System Vice Operating and Laurie Martha Katie Hope
Health Chart Executive Chief Witliam
Program Ambulatory Derdistry DDS DMD Hygienist Harne Assistant Turner
Integrated Care Organizational of Chen, Dentist Christopher Brendemuhl, Dental John Dental Jamia
HIV Operabons Patel Director John
Maricopa Director Shashikala
Ambulatory Alvarado
Services Jones Dental Receptionist
Manager Lou Patrida
Dental Mary

DEPARTMENT OF HEALTH & HUMAN SERVICES Health Resources and Services
Administration
Office of Federal Assistance Management Rockville, MD 20857
DEC 2 3 2113
TO; HRSA Grantees
FROM: Chief Grants Management Officer, HRSA
Associate Administrator, OFAM
SUBJECT: Pilot Program for Enhancement of Employee Whistleblower Protection
Congress has enacted many whistleblower protection statutes to encourage employees to report
fraud, waste, and abuse. You should be aware that the latest whistleblower protection statutes
went into effect on July 1, 2013. The statute, 41 U.S.C. § 4712, applies to all employees
working for contractors, grantees, subcontractors, and subgrantees on federal grants and
contracts. The National Defense Authorization Act (NDAA) for Fiscal Year (FY) 2013 (Pub. L.
112-239, enacted January 2, 2013) mandates a pilot program entitled "Pilot Program for
Enhancement of Contractor Employee Whistleblower Protections." This program requires all
grantees, their subgrantees, and subcontractors to:
1. Inform their employees working on any federal award they are subject to the
whistleblower rights and remedies of the pilot program;
2. Inform their employees in writing of employee whistleblower protections under 41
U.S.C. § 4712 in the predominant native language of the workforce: and.
3. Contractors and grantees will include such requirements in any agreement made with a
subcontractor or subgrantee.
The statute (41 U.S.C. § 4712) states that an "employee of a contractor, subcontractor, grantee
[or subgrantee] may not be discharged, demoted, or otherwise discriminated against as a reprisal
for "whistleblowing," In addition, whistleblower protections cannot be waived by any
agreement, policy, form, or condition of employment.
Whistleblowing is defined as making a disclosure "that the employee reasonably believes is
evidence of any of the following:
• Gross mismanagement of a federal contract or grunt;
• A gross waste of federal funds;

FIRSA Grantees
Page 2
• An abuse of authority relating to a federal contract or grant;
• A substantial and specific danger to public health or safety; or
• A violation of law, rule, or regulation related to a federal contract or grant (including the
competition for, or negotiation of, a contract or grant).
To qualify under the statute, the employee's disclosure must be made to:
• A Member of Congress, or a representative of a Congressional committee;
• An Inspector General;
• The Government Accountability Office;
• A federal employee responsible for contract or grant oversight or management at the
relevant agency;
• An official from the Department of Justice, or other law enforcement agency;
• A court or grand jury; or
• A management official or other employee of the contractor, subcontractor, grantee, or
subgrantee who has the responsibility to investigate, discover, or address misconduct.
The requirement to comply with, and info= all employees of, the Pilot Program for
Enhancement of Contract Employee Whistleblower Protections" is in effect for all grants,
contracts, subgrants, and subcontracts issued beginning July I, 2013 through January I, 2017.
MichaelUi. Nelson